(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/116024 A1

(51) International Patent Classification[7]: C07D 413/14, A61K 31/4439, A61P 31/04

(21) International Application Number: PCT/GB2005/002059

(22) International Filing Date: 24 May 2005 (24.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0411595.2	25 May 2004 (25.05.2004)	GB
0500056.7	5 January 2005 (05.01.2005)	GB

(71) Applicant *(for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG only)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GRAVESTOCK, Michael, Barry** [GB/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **CARCANAGUE, Daniel, Robert** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 3- (4- (2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL) PHENYL) -5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVAIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS

(57) Abstract: Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R^1, R^2, R^3, and R^4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

WO 2005/116024 A1

3-(4-(2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL)PHENYL)-5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing substituted oxazolidinone and isoxazoline rings. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.

Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.

The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β-lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H.influenzae and M.catarrhalis.

Certain antibacterial compounds containing an oxazolidinone ring have been described in the art (for example, Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and 1989, 32(8), 1673-81; Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165). Bacterial resistance to known antibacterial agents may develop, for example, by (i) the evolution of active binding sites in the bacteria rendering a previously active pharmacophore less effective

or redundant, and/or (ii) the evolution of means to chemically deactivate a given pharmacophore, and/or (iii) the evolution of efflux pathways. Therefore, there remains an ongoing need to find new antibacterial agents with a favourable pharmacological profile, in particular for compounds containing new pharmacophores.

Our application WO 03/022824 describes a class of bi-aryl antibiotic compounds containing two substituted oxazolidinone and/or isoxazoline rings which has useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and/or linezolid and/or against E. faecium strains resistant to both aminoglycosides and clinically used β-lactams, but also to fastidious Gram negative strains such as H.influenzae, M.catarrhalis, mycoplasma spp. and chlamydial strains. These compounds thus contain two groups capable of acting as pharmacophores, which may independently bind at pharmacophore binding sites, or alternatively one of the groups may bind at a pharmacophore binding site whilst the other group fulfills a different role in the mechanism of action.

In that patent application, the oxazolidinone and isoxazoline rings each bear a substituent in the 5-position selected from those substituents generally recognised in the art to be suitable for such antibacterial agents, for example methylacetamides (see for example, WO 93/09103), methylamino-linked heterocycles (see for example WO 00/21960) and heterocyclylmethyl groups (see for example WO 01/81350).

Oxazolidinone containing compounds which are mono amine oxidase (MAO) inhibitors are also known (see for example GB 2028306A). Indeed inhibition of MAO is a potential cause of unwanted side effects in oxazolidinone antibacterial agents and thus it is generally desirable that this property is minimised in any potential antibacterial agent (see for example WO 03/072575). In particular, oxazolidinones with amine and ether containing substituents in the 5-position of the oxazolidinone ring have been described as having potent MAO inhibitory activity (see for example, GB 2028306A; J. Pharm Pharmacol, 1983, 161-165; J. Am. Chem. Soc, 111, 8891-8895; and references therein).

We have now unexpectedly discovered that a class of bi-aryl compounds containing one oxazolidinone and one isoxazoline ring, bearing ether or substituted ether sidechains on the isoxazoline and a triazole ring on the oxazolidinone, possess acceptable levels of MAO inhibition whilst having useful antibacterial activity.

Accordingly the present invention provides a compound of the formula (I), or a pharmaceutically-acceptable salt, or pro-drug thereof,



(I)

wherein:

R^1 is selected from hydrogen, halogen, cyano, methyl, cyanomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methylthio, and (2-4C)alkynyl;

R^2 and R^3 are independently selected from hydrogen, fluoro, chloro and trifluoromethyl;

R^4 is selected from cyanomethyl, carboxymethyl, $-CH_2C(O)NR^5R^6$ and (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy, hydroxy(2-4C)alkoxy, cyano, $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$];

R^5 and R^6 are independently selected from hydrogen, methyl, cyclopropyl (optionally substituted with methyl), carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substitued on the (1-4C)alkyl chain with carboxy);

or R^5 and R^6 together with a nitrogen to which they are attached form a 4, 5 or 6 membered, saturated heterocyclyl ring, optionally containing 1 further heteroatom (in addition to the linking N atom) independently selected from O, N and S, wherein a $-CH_2-$ group may optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom (providing the nitrogen to which R^5 and R^6 are attached is not thereby quaternised) by 1 or 2 (1-4C)alkyl groups.

In another aspect, the invention relates to compounds of formula (I) as hereinabove defined or to a pharmaceutically acceptable salt.

In another aspect, the invention relates to compounds of formula (I) as hereinabove defined or to a pro-drug thereof. Suitable examples of pro-drugs of compounds of formula (I) are in-vivo hydrolysable esters of compounds of formula (I). Therefore in another aspect, the invention relates to compounds of formula (I) as hereinabove defined or to an in-vivo hydrolysable ester thereof.

In this specification the term 'alkyl' includes straight chain and branched structures. For example, (1-4C)alkyl includes propyl and isopropyl. However, references to individual alkyl groups such as "propyl" are specific for the straight chain version only, and references to individual branched chain alkyl groups such as "isopropyl" are specific for the branched chain version only. A similar convention applies to other radicals, for example halo(1-4C)alkyl includes 1-bromoethyl and 2-bromoethyl.

In this specification, the terms 'alkenyl' and 'cycloalkenyl' include all positional and geometrical isomers.

Where optional substituents are chosen from "0, 1, 2 or 3" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. An analogous convention applies to substituents chose from "0, 1 or 2" groups and "1 or 2" groups.

It will be understood that a 4, 5 or 6 membered, saturated heterocyclyl ring containing 1 or 2 heteroatoms independently selected from O, N and S (whether or not one of those heteroatoms is a linking N atom), as defined in any definition herein, does not contain any O-O, O-S or S-S bonds.

Within this specification composite terms are used to describe groups comprising more than one functionality such as (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkyl. Such terms are to be interpreted in accordance with the meaning which is understood by a person skilled in the art for each component part. For example (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkyl includes methoxymethoxymethyl, ethoxymethoxypropyl and propoxyethoxymethyl.

It will be understood that where a group is defined such that is optionally substituted by more than one substituent, then substitution is such that chemically stable compounds are formed. For example, a trifluoromethyl group may be allowed but not a trihydroxymethyl group. This convention is applied wherever optional substituents are defined.

There follow particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore, or hereinafter. For the avoidance of doubt each stated species represents a particular and independent aspect of this invention.

Examples of **(1-4C)alkyl** include methyl, ethyl, propyl, isopropyl and t-butyl; examples of **(2-4C)alkyl** include ethyl, propyl, isopropyl and t-butyl; examples of **(1-6C)alkyl** include methyl, ethyl, propyl, isopropyl, t-butyl, pentyl and hexyl; examples of

hydroxy(1-4C)alkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl; examples of **hydroxy(2-4C)alkyl** include 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxyisopropyl and 2-hydroxyisopropyl; examples of **(1-4C)alkoxycarbonyl** include methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; examples of **(2-4C)alkenyl** include allyl and vinyl; examples of **(2-4C)alkynyl** include ethynyl and 2-propynyl; examples of **(1-4C)alkanoyl** include formyl, acetyl and propionyl; examples of **(1-4C)alkoxy** include methoxy, ethoxy and propoxy; examples of **(1-6C)alkoxy** and **(1-10C)alkoxy** include methoxy, ethoxy, propoxy and pentoxy; examples of **(1-4C)alkylthio** include methylthio and ethylthio; examples of **(1-4C)alkylamino** include methylamino, ethylamino and propylamino; examples of **di-((1-4C)alkyl)amino** include dimethylamino, N-ethyl-N-methylamino, diethylamino, N-methyl-N-propylamino and dipropylamino; examples of **halo** groups include fluoro, chloro and bromo; examples of **(1-4C)alkoxy-(1-4C)alkoxy** and **(1-6C)alkoxy-(1-6C)alkoxy** include methoxymethoxy, 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy; examples of **(1-4C)alkanoylamino** and **(1-6C)alkanoylamino** include formamido, acetamido and propionylamino; examples of **(1-4C)alkylS(O)$_q$-** wherein q is 0, 1 or 2 include methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl and ethylsulfonyl; examples of **hydroxy-(2-4C)alkoxy** include 2-hydroxyethoxy and 3-hydroxypropoxy; examples of **(1-6C)alkoxy-(1-6C)alkyl** and **(1-4C)alkoxy(1-4C)alkyl** include methoxymethyl, ethoxymethyl and propoxyethyl; examples of **(1-4C)alkylcarbamoyl** include methylcarbamoyl and ethylcarbamoyl; examples of **di((1-4C)alkyl)carbamoyl** include di(methyl)carbamoyl and di(ethyl)carbamoyl; examples of **halo** groups include fluoro, chloro and bromo; examples of **halo(1-4C)alkyl** include, halomethyl, 1-haloethyl, 2-haloethyl, and 3-halopropyl; examples of **dihalo(1-4C)alkyl** include difluoromethyl and dichloromethyl; examples of **trihalo(1-4C)alkyl** include trifluoromethyl; examples of **amino(1-4C)alkyl** include aminomethyl, 1-aminoethyl, 2-aminoethyl and 3-aminopropyl; examples of **cyano(1-4C)alkyl** include cyanomethyl, 1-cyanoethyl, 2-cyanoethyl and 3-cyanopropyl; examples of **(1-4C)alkanoyloxy** include acetoxy, propanoyloxy; examples of **(1-6C)alkanoyloxy** include acetoxy, propanoyloxy and tert-butanoyloxy; examples of **(1-4C)alkylaminocarbonyl** include methylaminocarbonyl and ethylaminocarbonyl; examples of **di((1-4C)alkyl)aminocarbonyl** include dimethylaminocarbonyl and diethylaminocarbonyl.

Where optional substituents are listed such substitution is preferably not geminal disubstitution unless stated otherwise. If not stated elsewhere, suitable optional substituents for a particular group are those as stated for similar groups herein.

Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, N-methyl d-glucamine and amino acids such as lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

The compounds of the invention may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the invention. A prodrug may be used to alter or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains a suitable group or substituent which can be derivatised to form a prodrug. Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the invention or a pharmaceutically-acceptable salt thereof. Further examples of pro-drugs include in-vivo hydrolysable amides of a compound of the invention or a pharmaceutically-acceptable salt thereof.

Various forms of prodrugs are known in the art, for examples see:

a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);

b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);

c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);

d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and

e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

Suitable pro-drugs for pyridine or triazole derivatives include acyloxymethyl pyridinium or triazolium salts eg halides; for example a pro-drug such as:





(Ref: T.Yamazaki et al . 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002; Abstract F820).

Suitable pro-drugs of hydroxyl groups are acyl esters of acetal-carbonate esters of formula RCOOC(R,R')OCO-, where R is (1-4C)alkyl and R' is (1-4C)alkyl or H. Further suitable prodrugs are carbonate and carabamate esters RCOO- and RNHCOO-.

An in-vivo hydrolysable ester of a compound of the invention or a pharmaceutically-acceptable salt thereof containing a carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol.

Suitable pharmaceutically-acceptable esters for carboxy include (1-6C)alkoxymethyl esters for example methoxymethyl, (1-6C)alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, (3-8C)cycloalkoxycarbonyloxy(1-6C)alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-onylmethyl esters for example 5-methyl-1,3-dioxolan-2-ylmethyl; and (1-6C)alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An in-vivo hydrolysable ester of a compound of the invention or a pharmaceutically-acceptable salt thereof containing a hydroxy group or groups includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α-acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include (1-10C)alkanoyl (for example (1-4C)alkanoyl), benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, (1-10C)alkoxycarbonyl (to give alkyl carbonate esters), di-(1-4C)alkylcarbamoyl and N-(di-(1-4C)alkylaminoethyl)-N-(1-4C)alkylcarbamoyl (to give carbamates), di-(1-4C)alkylaminoacetyl, carboxy(2-5C)alkylcarbonyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include

chloromethyl or aminomethyl, (1-4C)alkylaminomethyl and di-((1-4C)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4-position of the benzoyl ring. Other interesting in-vivo hydrolysable esters include, for example, $R^A C(O)O(1\text{-}6C)alkyl\text{-}CO$- (wherein R^A is for example, optionally substituted benzyloxy-(1-4C)alkyl, or optionally substituted phenyl; suitable substituents on a phenyl group in such esters include, for example, 4-(1-4C)piperazino-(1-4C)alkyl, piperazino-(1-4C)alkyl and morpholino-(1-4C)alkyl.

Further suitable in-vivo hydrolysable esters are those formed from amino acids. For examples, esters formed by reaction of a hydroxy group of a compound with the carboxylic acid of an amino acid. By the term "amino acid" herein we mean any α- or other amino substituted acid, naturally occurring or otherwise ie. non-naturally occurring, and derivatives thereof such as those formed by substitution (for example by alkylation on the nitrogen of the amino group). The use of either a natural or a non-natural amino acid represent particular and independent aspects of the invention. Examples of suitable α– amino acids and derivatives thereof, are valine, leucine, iso-leucine, N-methyl isoleucine, N-tert-butyl-isoleucine, lysine, glycine, N-methylglycine, N,N-dimethyl glycine, alanine, gluamine, asparagine, proline, and phenylalanine. In one embodiment, preferred amino acids are naturally occurring α-amino acids and *N*-alkylated derivatives thereof.

The use of amino acids having neutral and/or basic side chains represent particular and independent aspects of the invention.

Suitable in-vivo hydrolysable esters of a compound of the formula (I) are described as follows. For example, a 1,2-diol may be cyclised to form a cyclic ester of formula (PD1) or a pyrophosphate of formula (PD2), and a 1,3-diol may be cyclised to form a cyclic ester of the formula (PD3):



(PD1) **(PD2)** **(PD3)**

Esters of compounds of formula (I) wherein the HO- function/s in (PD1), (PD2) and (PD3) are protected by (1-4C)alkyl, phenyl or benzyl are useful intermediates for the preparation of such pro-drugs.

Further in-vivo hydrolysable esters include phosphoramidic esters, and also compounds of invention in which any free hydroxy group independently forms a phosphoryl (npd is 1) or phosphiryl (npd is 0) ester of the formula (PD4) :



(PD4)

For the avoidance of doubt, phosphono is $-P(O)(OH)_2$; (1-4C)alkoxy(hydroxy)-phosphoryl is a mono-(1-4C)alkoxy derivative of $-O-P(O)(OH)_2$; and di-(1-4C)alkoxyphosphoryl is a di-(1-4C)alkoxy derivative of $-O-P(O)(OH)_2$.

Useful intermediates for the preparation of such esters include compounds containing a group/s of formula (PD4) in which either or both of the -OH groups in (PD1) is independently protected by (1-4C)alkyl (such compounds also being interesting compounds in their own right), phenyl or phenyl-(1-4C)alkyl (such phenyl groups being optionally substituted by 1 or 2 groups independently selected from (1-4C)alkyl, nitro, halo and (1-4C)alkoxy).

Thus, prodrugs containing groups such as (PD1), (PD2), (PD3) and (PD4) may be prepared by reaction of a compound of invention containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection.

Other suitable prodrugs include phosphonooxymethyl ethers and their salts, for example a prodrug of R-OH such as:



When a compound of invention contains a number of free hydroxy group, those groups not being converted into a prodrug functionality may be protected (for example, using a t-butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used to selectively phosphorylate or dephosphorylate alcohol functionalities.

Examples of pro-drugs for an amino group include in-vivo hydrolysable amides or a pharmaceutically-acceptable salt thereof. Suitable in-vivo hydrolysable groups include N-

carbomethoxy and N-acetyl. Such amides may formed by reaction of an amino (or alkylamino) group with an activated acyl derivative such as an activated ester or an acid chloride, for example, (1-6C)alkanoylchlorides (such as tBuCOCl or acetyl chloride), or substituted derivatives thereof.

A suitable value for an in-vivo hydrolysable amide of a compound of the formula (I) containing a carboxy group is, for example, a *N*-C_{1-6}alkyl or *N,N*-di-C_{1-6}alkyl amide such as *N*-methyl, *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethyl amide. Further suitable values for in-vivo hydrolysable amides of a compound of the formula (I) containing an amine or carboxy group are in-vivo hydrolysable amides formed by reaction with amino-acids, as defined and described herein for in-vivo hydrolysable esters.

Where pharmaceutically-acceptable salts of an in-vivo hydrolysable ester or amide may be formed this is achieved by conventional techniques. Thus, for example, compounds containing a group of formula (PD1), (PD2), (PD3)and/or (PD4) may ionise (partially or fully) to form salts with an appropriate number of counter-ions. Thus, by way of example, if an in-vivo hydrolysable ester prodrug of a compound of invention contains two (PD4) groups, there are four HO-P- functionalities present in the overall molecule, each of which may form an appropriate salt (i.e. the overall molecule may form, for example, a mono-, di-, tri- or tetra-sodium salt).

In one aspect, suitable pro-drugs of the invention are in-vivo hydrolysable esters such as (1-4C)alkyl esters; (1-4C)alkyl esters substituted with (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy, carboxy, (1-4C)alkyl esters, amino, (1-4C)alkylamino, di(1-4C)alkylamino, tri(1-4C)alkylamino (thereby containing a quaternised nitrogen atom), aminocarbonyl, carbamates, amides or heterocyclyl groups (for example, an ester formed by reaction of a hydroxy group in R^4 or R^5 with methoxy acetic acid, methoxypropionic acid, adipic acid momethylester, 4-dimethylaminobutanoic acid, 2-methylaminobutanoic acid, 5-amino pentanoic acid, β-alanine, *N,N*-diethylalanine, valine, leucine, iso-leucine, *N*-methyl isoleucine, *N*-tert-butyl-isoleucine, lysine, glycine, *N,N*-dimethyl glycine, alanine, sarcosine, glutamine, asparagine, proline, phenylalanine, nicotinic acid, nicotinic acid –*N*-oxide, pyrimidine-carboxylic acid (for example pyrimidine-5-carboxylic acid), pyrazine-carboxylic acid (for example pyrazine-2-carboxylic acid), or piperidine-4-carboxylic acid); (3-6C)cycloalkyl esters (optionally substituted by a (1-4C)alkoxycarbonyl, alkoxy or carboxy group); carbonates (for example (1-4C)alkylcarbonates and such carbonates substituted by (1-4C)alkoxy or di(1-4C)alkyl)amino); sulfates; phosphates and phosphate esters; and carbamates (see for example Example 10); and

pharmaceutically acceptable salts thereof.

Further suitable pro-drugs are those formed by reaction of a hydroxy group in R^4 or R^5 with carbonates, particularly alkoxysubstituted alkyl carbonates such as methoxypropylcarbonate.

Further suitable pro-drugs are esters formed by reaction of a hydroxy group in R^4 or R^5 with methoxy acetic acid, methoxypropionic acid, adipic acid momethylester, 4-dimethylaminobutanoic acid, 2-methylaminobutanoic acid, 5-amino pentanoic acid, β-alanine, *N,N*-diethylalanine, valine, leucine, iso-leucine, *N*-methyl isoleucine, *N*-tert-butyl-isoleucine, lysine, glycine, *N,N*-dimethyl glycine, alanine, sarcosine, glutamine, asparagine, proline, phenylalanine, nicotinic acid, nicotinic acid –*N*-oxide, pyrimidine-5-carboxylic acid, pyrazine-2-carboxylic acid, or piperidine-4-carboxylic acid, 2-carboxy-cyclohexane-1-carboxylic acid; and pharmaceutically acceptable salts thereof.

Particular compounds of the invention are in-vivo hydrolysable esters formed from amino acids, and pharmaceutically acceptable salts thereof.

Further particular compounds of the invention are in-vivo hydrolysable esters formed from 4-dimethylaminobutanoic acid, 2-methylaminobutanoic acid, 5-amino pentanoic acid, β-alanine, *N,N*-diethylalanine, valine, leucine, iso-leucine, *N*-methyl isoleucine, *N*-tert-butyl-isoleucine, lysine, glycine, *N,N*-dimethyl glycine, alanine, sarcosine, glutamine, asparagine, proline, phenylalanine; and pharmaceutically acceptable salts thereof.

Further particular compounds of the invention are in-vivo hydrolysable esters formed from valine, leucine, iso-leucine, *N*-methyl isoleucine, *N*-tert-butyl-isoleucine, lysine, glycine, *N,N*-dimethyl glycine, alanine, sarcosine, glutamine, asparagine, proline and phenylalanine; and pharmaceutically acceptable salts thereof.

Further suitable in-vivo hydrolysable esters are compounds of the formula (I) as hereinbefore described, wherein R^4 is $-CH_2C(O)OR^5$ or (2-4C)alkyl substituted with $-C(O)OR^5$ for R^5 not = H).

The compounds of the present invention have a chiral centre at the C-5 positions of the oxazolidinone and isoxazoline rings. The pharmaceutically active diastereomer is of the formula (Ia):



(Ia)

In one aspect a preferred diastereomer is of formula (Ib). In another aspect a preferred diastereomer is of formula (Ic).



(Ib)



(Ic)

If a mixture of epimers on the oxazolidinone chiral center is used, a larger amount (depending upon the ratio of the diastereoisomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer.

Furthermore, some compounds of the invention may have other chiral centres, for example on substituent R^4. It is to be understood that the invention encompasses all such optical and diastereoisomers, and racemic mixtures, that possess antibacterial activity. It is well known in the art how to prepare optically-active forms (for example by resolution of the racemic form by recrystallisation techniques, by chiral synthesis, by enzymatic resolution, by biotransformation or by chromatographic separation) and how to determine antibacterial activity as described hereinafter.

The invention relates to all tautomeric forms of the compounds of the invention that possess antibacterial activity.

It is also to be understood that certain compounds of the invention can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess antibacterial activity.

It is also to be understood that certain compounds of the invention may exhibit polymorphism, and that the invention encompasses all such forms which possess antibacterial activity.

As stated before, we have discovered a range of compounds that have good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram negative pathogens such as H.influenzae, M.catarrhalis, Mycoplasma and Chlamydia strains. The following compounds possess preferred pharmaceutical and/or physical and/or pharmacokinetic properties, for example solubility and/or bioavailability.

The substituted ethers of the invention generally have improved pharmaceutical and/or physical and/or pharmacokinetic properties, for example solubility and/or bioavailability in comparison to unsubstituted ethers, such as a simple methyl ether.

It will be appreciated that parameters such as solubility may be measured by any suitable method known in the art.

In one embodiment of the invention are provided compounds of formula (I), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I), in a further alternative embodiment are provided in-vivo hydrolysable esters of compounds of formula (I), and in a further alternative embodiment are provided pharmaceutically-acceptable salts of in-vivo hydrolysable esters of compounds of formula (I).

In one aspect, R^1 is selected from hydrogen, halogen, cyano, methyl, cyanomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethynyl and propynyl.

In another aspect, R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl.

In another aspect, R^1 is hydrogen.

In one aspect, R^2 and R^3 are independently hydrogen or fluoro.

In another aspect R^2 and R^3 are both hydrogen.

In another aspect one R^2 and R^3 is hydrogen and the other is fluorine.

In one embodiment R^4 is selected from cyanomethyl, carboxymethyl, $-CH_2C(O)NR^5R^6$, and (2-4C)alkyl [optionally substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy, hydroxy(2-4C)alkoxy, cyano, $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$].

In another aspect, R^4 is selected from cyanomethyl, carboxymethyl, and $-CH_2C(O)NR^5R^6$. In a further aspect, R^4 is selected from carboxymethyl, and $-CH_2C(O)NR^5R^6$.

In another aspect, R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy, hydroxy(2-4C)alkoxy, cyano, $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$].

In another aspect, R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy and hydroxy(2-4C)alkoxy].

In another aspect, R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$].

In a further aspect, R^4 is selected from carboxymethyl, $-CH_2C(O)NR^5R^6$ and (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, $-NR^5R^6$, $-NHS(O)_2R^5$, $-NHC(O)R^5$ and $-OC(O)R^5$].

In one aspect R^5 and R^6 are independently selected from hydrogen, methyl, cyclopropyl (optionally subsituted with methyl), carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy).

In another aspect, R^5 and R^6 are independently selected from hydrogen, methyl, carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy).

In another aspect, R^5 and R^6 are independently selected from hydrogen and (1-4C)alkyl.

In another aspect, R^5 and R^6 are independently selected from hydrogen, carboxymethyl and (2-4C)alkyl (substituted by a substituent selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy).

In another aspect, R^5 and R^6 are independently selected from hydrogen, carboxymethyl and (2-4C)alkyl (substituted by a substituent selected from carboxy, (1-4C)alkoxy and hydroxy).

In a further aspect, R^5 and R^6 together with a nitrogen to which they are attached form a 4, 5 or 6 membered, saturated heterocyclyl ring, optionally containing 1 further heteroatom (in addition to the linking N atom) independently selected from O, N and S, wherein a $-CH_2-$ group may optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom (providing the nitrogen to which R^5 and R^6 are attached is not thereby quaternised) by 1 or 2 (1-4C)alkyl groups.

Suitable optional substituents for such a ring comprising R^5 and R^6 together with a nitrogen to which they are attached are 1 or 2 methyl groups.

Suitable values for such a ring comprising R^5 and R^6 together with the nitrogen to which they are attached are azetidine, morpholine, piperazine, N-methylpiperazine, thiomorpholine (and derivatives thereof wherein the sulfur is oxidised to an S(O) or $S(O)_2$ group), piperidine, and pyrrolidine.

Further suitable values are morpholine, thiomorpholine, piperazine and N-methyl piperazine.

Further suitable values are morpholine, piperazine and N-methyl piperazine.

In another aspect, R^5 and R^6 are independently selected from hydrogen, methyl, 1 and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy);

or R^5 and R^6 together with a nitrogen to which they are attached form a morpholine or piperazine ring, optionally substituted with a methyl group.

In a preferred aspect of the invention, the compound of formula (I) is a compound of the formula (Ia).

In a further aspect of the invention, there is provided a compound of the formula (Ia) as hereinbefore defined, or a pharmaceutically-acceptable salt or pro-drug thereof, wherein:

R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl;

R^2 and R^3 are independently hydrogen or fluoro;

R^4 is selected from carboxymethyl, and $-CH_2C(O)NR^5R^6$;

R^5 and R^6 are independently selected from hydrogen, methyl, carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-

4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy).

In a further aspect of the invention, there is provided a compound of the formula (Ia) as hereinbefore defined, or a pharmaceutically-acceptable salt or pro-drug thereof, wherein:

R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl;

R^2 and R^3 are independently hydrogen or fluoro;

R^4 is selected from carboxymethyl, and $-CH_2C(O)NR^5R^6$;

R^5 and R^6 together with the nitrogen to which they are attached form a 4, 5 or 6 membered, saturated heterocyclyl ring, optionally containing 1 further heteroatom (in addition to the linking N atom) independently selected from O, N and S, wherein a $-CH_2-$ group may optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom (providing the nitrogen to which R^5 and R^6 are attached is not thereby quaternised) by 1 or 2 (1-4C)alkyl groups.

In a further aspect of the invention, there is provided a compound of the formula (Ia) as hereinbefore defined, or a pharmaceutically-acceptable salt or pro-drug thereof, wherein:

R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl;

R^2 and R^3 are independently hydrogen or fluoro;

R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy and hydroxy(2-4C)alkoxy].

In a further aspect of the invention, there is provided a compound of the formula (Ia) as hereinbefore defined, or a pharmaceutically-acceptable salt or pro-drug thereof, wherein:

R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl;

R^2 and R^3 are independently hydrogen or fluoro;

R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$];

R^5 and R^6 are independently selected from hydrogen, methyl, carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-

4C)alkyl chain with carboxy).

In a further aspect of the invention, there is provided a compound of the formula (Ia) as hereinbefore defined, or a pharmaceutically-acceptable salt or pro-drug thereof, wherein:

R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl;

R^2 and R^3 are independently hydrogen or fluoro;

R^4 is selected from (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$ and $-NR^5R^6$];

R^5 and R^6 together with a nitrogen to which they are attached form a 4, 5 or 6 membered, saturated heterocyclyl ring, optionally containing 1 further heteroatom (in addition to the linking N atom) independently selected from O, N and S, wherein a $-CH_2-$ group may optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom (providing the nitrogen to which R^5 and R^6 are attached is not thereby quaternised) by 1 or 2 (1-4C)alkyl groups.

Particular compounds of the present invention include each individual compound described in the Examples, each of which provides a further independent aspect of the invention. In another aspect of the invention, is provided any two or more of the Examples.

Process section:

In a further aspect the present invention provides a process for preparing a compound of invention or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.

For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. Resins may also be used as a protecting group.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

A compound of the invention, or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a compound of the invention, or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated by the following representative examples. Necessary starting materials may be obtained by standard procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March or Houben-Weyl, Methoden der Organischen Chemie). The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist. Information on the preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the certain Patent Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference; for example WO 94/13649; WO 98/54161; WO 99/64416; WO 99/64417; WO 00/21960; WO 01/40222; WO 01/94342; WO 03/022824, JP2003335762 and WO 03/006440.

In particular we refer to our PCT patent applications WO 99/64417 and WO 00/21960 wherein detailed guidance is given on convenient methods for preparing oxazolidinone compounds.

The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products.

Thus, the present invention also provides that the compounds of the invention and pharmaceutically-acceptable salts and *in vivo* hydrolysable esters thereof, can be prepared by a process (a) to (l); and thereafter if necessary:

i) removing any protecting groups;

ii) forming a pro-drug (for example an in-vivo hydrolysable ester); and/or

iii) forming a pharmaceutically-acceptable salt;

wherein said processes (a) to (l) are as follows (wherein the variables are as defined above unless otherwise stated):

a) by modifying a substituent in, or introducing a substituent into another compound of the invention by using standard chemistry (see for example, Comprehensive Organic Functional Group Transformations (Pergamon), Katritzky, Meth-Cohn & Rees); for example:
a hydroxy group may be converted into an acyloxy group, for instance an acetoxy group;
an acyloxy group may be converted into a hydroxy group or into the groups that may be obtained from a hydroxy group (either directly or through the intermediacy of a hydroxy group);
an 1,2,3-triazol-1-yl group may be converted by introduction of a new ring substituent or by refunctionalisation of an existing ring substituent, for instance by modifying the 4-substituent of a 4-substituted 1,2,3-triazol-1-yl group, or introducing a 4-substituent into an unsubstituted 1,2,3-triazol-1-yl group;

an alcohol group may be converted into an ether group by first converting into a leaving group such as a halide, or sulfonate ester such as a para toluenesulfonate and then further conversion to an ether by treatment with another alcohol under basic conditions;
an alcohol may be converted into an imidate such as a trifluoroacetimidate for example by treatment with trifluoroacetonitrile and base; the imidate may then be treated with another alcohol under acidic conditions to give an ether;
functionalized ether derivatives may be further modified for example by:
treating a carboxylic acid (or ester), or a ketone, or a Weinreb amide derivative with an organometallic derivative such as an alkyl Grignard or alkyl lithium reagent to give a tertiary alcohol, secondary alcohol or ketone derivative respectively;
by reducing a carboxylic acid, ester, ketone or aldehyde to give an alcohol;
by hydrolysis of an ester to an acid;
by treatment of an activated carboxylic acid derivative with an amine to give an amide;
by oxidizing an alkene to an epoxide, for example with a peracid,
by treating an epoxide with a nucleophile such as an amine, thiolate or alkoxide to give a 2-hydroxy amine, thioether, or ether;
by oxidizing a thioether to a sulfone or sulfoxide; by oxidizing an alkene to a 1,2-diol for example with osmium tetroxide;

by converting a 1,2-diol to an aldehyde for example with sodium periodate; alternatively an alkene can be ozonized (treatment with ozone followed by a reductant such as dimethylsulfide) to give an aldehyde;

by converting an aldehyde into an amine by reductive amination;

by oxidizing an alcohol to an aldehyde, ketone or carboxylic acid;

by acylation of an alcohol with an activated carboxylic acid derivative, isocyanate or chloroformate derivative to give an ester, carbamate or carbonate respectively;

by converting an alcohol into a leaving group such as a halide, or sulfonate ester such as a para toluenesulfonate and then further conversion to an amine precursor such as an azide or phthallimide, Mitsunobu-type conditions (for example triphenylphosphine, diethylazodicarboxylate, and hydrazoic acid) may alternatively be used for this type of transformation, the amine precursor may then be converted into an amine for example by reduction of the azide (for example with aqueous triphenylphosphine) or hydrolysis of the phthallimide (for example with hydrazine);

by converting an amino group into a substituted amino group, for example by alkylation, reductive alkylation, acylation, or sulfonylation;

an amine may be alkylated with an alkyl halide, or other activated agent such as a sulfonate ester; reductive alkylation of an amine may be carried out by treating with a carbonyl compound such as an aldehyde and a reducing agent such as sodium triacetoxy borohydride;

an amine may be acylated with an activated carboxylic acid derivative such as an acyl chloride or active ester to give an amide, an isocyanate derivative to give a urea, or a chloroformate derivative to give a carbamate;

an amine may be converted into an isocyanate for example by first converting to a formamide derivative, then treating with a dehydrating agent; the resulting isocyanate derivative may then be treated with an amine or alcohol to give a urea or carbamate derivative respectively;

an amine may be treated with an activated sulfonic acid derivative such as a sulfonyl chloride to give a sulfonamide;

b) by reaction of one part of a compound of formula (II) (wherein X is a leaving group useful in palladium [0]coupling, for example chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue) with one part of a compound IIa, again with a leaving group X (wherein Y is an ether or

functionalised derivative thereof), such that the pyridyl-phenyl bond replaces the phenyl-X and pyridyl-X bonds; such methods are now well known, see for instance S.P. Stanforth, Catalytic Cross-Coupling Reactions in Biaryl Synthesis, *Tetrahedron*, 54, **1998**, 263-303; J.K. Stille, *Angew Chem. Int. Ed. Eng.*, **1986**, *25*, 509-524; N. Miyaura and A Suzuki, *Chem. Rev.*, **1995**, *95*, 2457-2483; D. Baranano, G. Mann, and J.F. Hartwig, *Current Org. Chem.*, **1997**, *1*, 287-305; S.P. Stanforth, *Tetrahedron*, 54 **1998**, 263-303; P.R. Parry, C. Wang, A.S. Batsanov, M.R. Bryce; and B. Tarbit, *J. Org. Chem.*, **2002**, *67*, 7541-7543;



(II) **(IIa)**

the leaving group X may be the same or different in the two molecules (II) and (IIa); for example:



c) by reaction of a pyridyl-phenyl carbamate derivative (III) with an appropriately substituted oxirane to form an oxazolidinone ring, as illustrated below (wherein Y is as hereinbefore defined);



(III)

variations on this process in which the carbamate is replaced by an isocyanate or by an amine or/and in which the oxirane is replaced by an equivalent reagent X-CH_2CH(O-optionally protected)CH_2triazoleR_1 where X is a displaceable group are also well known in the art, for example,



(d) by reaction of a compound of formula (IV) :



(IV)

where X is a replaceable substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue with a compound of the formula (V):



(V)

wherein X' is a replaceable substituent (such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue) and wherein Y is as hereinbefore defined; wherein the substituents X and X' are chosen to be complementary pairs of substituents known in the art to be suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0);

e) by reaction of a 3-pyridylphenylbiaryl aldehyde derivative (VI) to form an isoxazoline ring at the undeveloped heteroaryl position, as illustrated below (wherein Y is as hereinbefore defined);



variations on this process in which the reactive intermediate (a nitrile oxide VII') is obtained other than by oxidation of an oxime (VII) are well known in the art;



(VII')

f) by formation of the triazole ring from a suitably functionalised intermediate in which the isoxazole-pyridyl-phenyl ring system is already formed, for example as illustrated by the scheme (wherein Y is as hereinbefore defined):


(Leaving group LG = e.g. mesylate,tosylate etc)
(ii)
Base
(i)
Mitsunobu reaction
(Leaving group = e.g. phosphine oxide generated in situ)
R1 both same
Heat
or
or
Y = alkyl or aryl
Z = alkyl, aryl or halo

g) by cycloaddition via the azide to acetylenes, for example by reacting azidomethyl oxazolidinones with terminal alkynes using Cu(I) catalysis in e.g. aqueous alcoholic solution at ambient temperatures to give 4-substituted 1,2,3-triazoles (V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless, Angew. Chem. Int. Ed., 2002, 41, 2596-2599), as illustrated below (wherein Y is as hereinbefore defined):



h) by reacting aminomethyloxazolidinones with 1,1-dihaloketone sulfonylhydrazones (Sakai, Kunihazu; Hida, Nobuko; Kondo, Kiyosi; *Bull. Chem. Soc. Jpn.*, **59**, *1986*, 179-183; Sakai, Kunikazu; Tsunemoto, Daiei; Kobori, Takeo; Kondo, Kiyoshi; Hido, Noboko EP 103840 A2 19840328), as illustrated below (wherein Y is as hereinbefore defined);



i) for R_1 as a 4-halo substituent, compounds of formula (I) may also be made by reacting azidomethyl oxazolidinones with halovinylsulfonyl chlorides at a temperature between 0 °C and 100 °C, either without solvent or in an inert diluent such as chlorobenzene, chloroform or dioxan, as illustrated below (wherein Y is as hereinbefore defined);



for the case when the halogen in the vinylsulfonylchloride reagent shown above is bromine see C. S. Rondestvedt, Jr. and P.K. Chang, *J. Amer. Chem. Soc.*, **77**, *1955*, 6532-6540; preparation of 1-bromo-1-ethenesulfonyl chloride by C. S. Rondestvedt, Jr., *J. Amer. Chem. Soc.*, **76**, *1954*, 1926-1929);

the cycloaddition reaction with 1-chloro-1-ethenesulfonyl chloride with an azide derivative in a process to form a compound of the formula (I) wherein R_1a is 4-chloro-1,2,3-triazole is carried out at 0 °C and 100 °C , preferably at room temperature, either in an inert solvent, preferably chlorobenzene, chloroform, or dioxan, or more preferably without a solvent;

I) an alternative route to a preferred single (subsituted)hydroxyalkyl epimer on the isoxazoline ring is via enantioselective esterase hydrolysis of a racemic mixture of esters at that pro-chiral centre, wherein the unwanted isomer may be recycled, for example:



The formation of compounds of formulae (II) and (IIa) as used in b) above:



(II) **(IIa)**

wherein each X is independently a leaving group useful in palladium [0]coupling, for example chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue may be carried out by any method known in the art for assembling such types of compounds, see for example WO 03/022824.

For example, where R_1a is a triazole ring, the 3 ring system of a compound of formula (II) may be assembled in a number of different ways as illustrated below for the unsubstituted triazole. Similar processes may be used for substituted triazoles and other values of R_1a. It will be appreciated that X in formula (II) as shown in the scheme below may be the same throughout the assembly of the 3 ring system, or may be altered at an appropriate point prior to coupling with the compound of formula (IIa); for example a compound of formula (II) wherein X is I or Br may be converted to a compound where X is a boronic acid or ester, or a

trimethylstannyl derivative and then coupled with a compound of formula (IIa) with a suitable substituent X, for example Br or I. Alternatively, a compound of the formula (IIa) wherein X is a boronic acid or ester, or a trimethylstannyl derivative, may be reacted with a compound of formula (II) wherein X is a suitable halo derivative such as I or Br.



(II)

Compounds of formula (IIa) may be derived from an oxime substituted pyridine derivative as shown below, wherein X is Br or I. The oxime derivative itself may be derived from simple halo-pyridine derivatives via aldehydo-halopyridines. Where a single enantiomer is required, the chiral centre on the isoxazole ring may be introduced by any means known in the art, for example by resolution of an ester group, for instance using an enzyme such as a lipase to achieve selectivity. This process is illustrated below for a butyl ester, however it will be appreciated that other alkyl or alkenyl esters may be used, and that resolution and hydrolysis may be achieved in a single step by enzyme catalysed selective ester hydrolysis. It will also be appreciated that resolution could be achieved by enzyme catalysed esterification of a hydroxy group, followed by hydrolysis to give the chiral alcohol shown below. The hydroxy group can then be elaborated to give the required compound of formula (IIa). It will be appreciated that X in formula (IIa) as shown in the scheme below may be the same throughout the assembly of the two ring system, or may be altered at an appropriate point prior to coupling with the compound of formula (II):



The formation of the OR^4 substituent from a hydroxymethyl substituent may be carried out at any stage of the synthetic sequence with protection and deprotection as necessary. Suitable synthetic precursors to the OR^4 group are for example the hydroxyl group, halo group [or other leaving group (LG) such as a mesylate or tosylate ester] and imidates such as trifluoroacetimidate. Examples of ether formation transformations are below.

It will be appreciated that the synthetic sequences shown in the scheme below may be applied at any appropriate stage during the assembly of the compound and thus that G in the scheme below may represent suitably substituted pyridyl, pyridyl-phenyl, pyridyl-phenyl-oxazolidinone or pyridyl-phenyl-oxazolidinone-methyltriazole ring systems;



When compounds of the invention require further transformation of the group R_4a to yield the desired OR^4 group, any reaction sequences well-known in the art may be used, for example:


RMgX
NaBH4
basic
or acidic
hydrolysis
RR'NH
coupling agent
OsO4
NaIO4
RCO3H
R2BH;
H2O2
n=2
NaBH4
n= 1
RR'NH
Na(OAc)3BH
NuH
acylation
or alkylation
PPh3
CCl4
or
RSO2Cl
base
Nu = nucleophile such as amine, thiolate, or alkoxide
NuH
NaN3
PPH3 / H2O
acylation
or alkylation
or sulfonylation

Compounds of the formula (IIa) where in X is a boronic acid or ester and Y is OR^4 are novel and form an independent aspect of the invention. Particular compounds of this aspect of the invention are compounds of the formula (IIa) wherein R_4 is as defined in any of the aspects or embodiments of the invention described hereinbefore or hereinafter.

Compounds of the formula (IIa) where in X is a halogen and Y is OR^4 are novel and form an independent aspect of the invention. Particular compounds of this aspect of the invention are Intermediates 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28.

It will be understood that by "X is a boronic acid or ester" means X is the group $-B(OR^A)(OR^B)$, wherein R^A and R^B are independently selected from hydrogen and a (1-4C)alkyl group (such as methyl, ethyl and isopropyl), or R^A and R^B together form a 2 or 3 carbon bridge between the two oxygen atoms attached to the boron atom to form a 5- or 6-membered ring respectively (wherein the 2 or 3 carbon bridge is optionally substituted by 1 to 4 methyl groups, for example to form a 1,1,2,2-tetramethylethylene bridge), or R^A and R^B together form a 1,2-phenyl group (thereby giving a catechol ester).

The removal of any protecting groups, the formation of a pharmaceutically-acceptable salt and/or the formation of an in-vivo hydrolysable ester or amide are within the skill of an ordinary organic chemist using standard techniques. Furthermore, details on the these steps, for example the preparation of in-vivo hydrolysable ester prodrugs has been provided, for example, in the section above on such esters.

When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.

Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.

Compounds of the formula (II) wherein X = Br (formula (IIc) may be made from compounds of the formula (II) wherein X = H (formula (IIb) by direct bromination of a solution of the compound of formula (IIb) using bromine generaterd in situ from a bromate, a bromide and an acid (wherein each X is independently H or F and Rp is selected from

hydrogen, halogen, cyano, methyl, cyanomethyl, fluoromethyl, difluoromethyl, trifluoromethyl and –Si[(1-4C)alkyl]$_3$).



(IIc)



(IIb)

It will be appreciated that producing bromine in the reaction medium, for example by the reaction between a bromate, a bromide and acid, according to the reaction:

$BrO_3^- + 6H^+ + 5Br^- \rightarrow 3Br_2 + 3H_2O$

is a convenient way to circumvent problems associated with degradation of bromine solutions with time.

Conveniently, the acid and bromide may be provided together by use of hydrobromic acid. Suitably the bromide is added as a solution in water, for example an aqueous solution of hydrobromic acid, such as a 48% w/w aqueous hydrobromic acid solution. Any convenient concentration of such a solution may be used.

Conveniently the bromate is an alkali metal bromate, such as potassium bromate or sodium bromate. Suitably the bromate is added as a solution in water.

The compound of formula (IIb) may be dissolved in any suitable organic solvent. In this context, suitable means that the organic solvent must be be miscible with water and must not react with the other reagents.

A suitable solvent is acetic acid. The compound of formula (IIb) may be dissolved in a mixture of said suitable organic solvent, such as acetic acid, and water.

Conveniently, the aqueous solution of bromide is added to the solution of the compound of formula (IIb), then the solution of bromate is added.

The reaction between bromate and bromide in the presence of acid is exothermic. Conveniently, a vessel containing the reaction mixture may be cooled, for instance in an ice-bath, but maintenance at a particular temperature is not essential for the yield or quality of the product produced. Conveniently a vessel containing the reaction mixture is cooled in an ice-bath such that the temperature of the reaction ranges between 10 and 30°C during the addition of bromate.

Suitably slight molar excesses of bromate and bromide are used in comparison to the quantity of the compound of formula (IIb) used.

The rate of addition of the bromate solution is not critical. Conveniently, it is added at a rate such that the temperature of the reaction is maintained between 10 and 30°C during the addition of bromate.

The reaction mixture may be stirred, for example at about ambient temperature, until the reaction is complete. Typically, the reaction may take 3-4 hours to complete, including the time required for addition of bromate.

After the reaction is complete, it is desirable to remove any excess bromine generated before isolation of the product. Conveniently this may be achieved by addition of a solution of metabisulfite, for example a solution of sodium metabisulfite in water. Sufficient metabisulfite is added to react with any residual bromine.

The product may be isolated by any convenient means, for example by filtration from the reaction mixture, or by dissolution into another organic solvent and appropriate washing and evaporation. If the product solidifies from the reaction mixture, it may be convenient to re-dissolve it (for example by heating the solution, for example to about 80-85 °C) and allow crystallisation in a controlled manner.

According to a further aspect of the invention, there is provided a process for forming a compound of the formula (IIc) from a compound of the formula (IIb) as hereinbefore defined, said process comprising treatment of a solution of the compound of formula (IIb) with an alkali metal bromate, and hydrobromic acid.

According to a further aspect of the invention, there is provided a process for forming a compound of the formula (IIc) from a compound of the formula (IIb) as hereinbefore defined, said process comprising:

a) treatment of a solution of the compound of formula (IIb) in a mixture of water and a suitable organic solvent with aqueous hydrobromic acid; and

b) addition of an aqueous solution of an alkali metal bromate.

According to a further aspect of the invention, there is provided a process for forming a compound of the formula (IIc) from a compound of the formula (IIb) as hereinbefore defined, said process comprising:

a) treatment of a solution of the compound of formula (IIb) in a mixture of water and a suitable organic solvent with aqueous hydrobromic acid;

b) addition of an aqueous solution of an alkali metal bromate; and

c) addition of a solution of sodium metabisulfite to react with any excess bromine.

According to a further aspect of the invention, there is provided a process for forming a compound of the formula (IIc) from a compound of the formula (IIb) as hereinbefore defined, said process comprising:

a) treatment of a solution of the compound of formula (IIb) in a mixture of water and a suitable organic solvent with aqueous hydrobromic acid;

b) addition of an aqueous solution of an alkali metal bromate;

c) addition of a solution of sodium metabisulfite to react with any excess bromine;

d) isolation of the product compound of the formula (IIc).

According to a further aspect of the invention, there is provided a process for forming a compound of the formula (IIc) from a compound of the formula (IIb) as hereinbefore defined, said process comprising:

a) treatment of a solution of the compound of formula (IIb) in a mixture of water and a suitable organic solvent with aqueous hydrobromic acid;

b) addition of an aqueous solution of an alkali metal bromate;

c) addition of a solution of sodium metabisulfite to react with any excess bromine;

d) isolation of the product compound of the formula (IIc) by heating the mixture resulting from step c) until any solid has dissolved and then cooling the solution until the compound of the formula (IIc) crystallises.

According to a further feature of the invention there is provided a compound of the invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof for use in a method of treatment of the human or animal body by therapy.

According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

The invention also provides a compound of the invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament; and the use of a compound of the invention of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal, such as man.

In order to use a compound of the invention, an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, (hereinafter in this section relating to pharmaceutical composition "a compound of this invention") for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the invention, an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, and a pharmaceutically-acceptable diluent or carrier.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration as eye-drops, for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, sub-lingual, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain (ie through co-formulation) or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, ß-lactams, macrolides, quinolones or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also be co-formulated or co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents. Compounds of this invention may also be co-formulated or co-administered with a vitamin, for example Vitamin B, such as Vitamin B2, Vitamin B6, Vitamin B12 and folic acid. Compounds of the invention may also be formulated or co-administered with cyclooxygenase (COX) inhibitors, particularly COX-2 inhibitors.

In one aspect of the invention, a compound of the invention is co-formulated with an antibacterial agent which is active against gram-positive bacteria.

In another aspect of the invention, a compound of the invention is co-formulated with an antibacterial agent which is active against gram-negative bacteria.

In another aspect of the invention, a compound of the invention is co-administered with an antibacterial agent which is active against gram-positive bacteria.

In another aspect of the invention, a compound of the invention is co-administered with an antibacterial agent which is active against gram-negative bacteria.

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents. A pharmaceutical composition to be dosed intravenously may contain advantageously (for example to enhance stability) a suitable bactericide, antioxidant or reducing agent, or a suitable sequestering agent.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example

heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol. Solubility enhancing agents, for example cyclodextrins may be used.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 50 mg to 5 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 200 mg to about 2 g of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 1mg and 1g of a compound of this invention, preferably between 100mg and 1g of a compound. Especially preferred is a tablet or capsule which contains between 50mg and 800mg of a compound of this invention, particularly in the range 100mg to 500mg.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example an injection which contains between 0.1% w/v and 50% w/v (between 1mg/ml and 500mg/ml) of a compound of this invention.

Each patient may receive, for example, a daily intravenous, subcutaneous or intramuscular dose of 0.5 $mgkg^{-1}$ to 20 $mgkg^{-1}$ of a compound of this invention, the composition being administered 1 to 4 times per day. In another embodiment a daily dose of 5 $mgkg^{-1}$ to 20 $mgkg^{-1}$of a compound of this invention is administered. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient may receive a daily oral dose which may be approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

Antibacterial Activity :

The pharmaceutically-acceptable compounds of the present invention are useful antibacterial agents having a good spectrum of activity in vitro against standard Gram-positive organisms, which are used to screen for activity against pathogenic bacteria. Notably, the pharmaceutically-acceptable compounds of the present invention show activity against enterococci, pneumococci and methicillin resistant strains of S.aureus and coagulase negative staphylococci, together with haemophilus and moraxella strains. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system.

The (antibacterial) properties of the compounds of the invention may also be demonstrated and assessed in-vivo in conventional tests, for example by oral and/or intravenous dosing of a compound to a warm-blooded mammal using standard techniques.

The following results were obtained on a standard in-vitro test system. The activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot. Typically, compounds are active in the range 0.01 to 256 μg/ml.

Staphylococci were tested on agar, using an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C for 24 hours - standard test conditions for the expression of methicillin resistance.

Streptococci and enterococci were tested on agar supplemented with 5% defibrinated horse blood, an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C in an atmosphere of 5% carbon dioxide for 48 hours - blood is required for the growth of some of the test organisms. Fastidious Gram negative organisms were tested in Mueller-Hinton broth, supplemented with hemin and NAD, grown aerobically for 24 hours at 37°C, and with an innoculum of $5x10^4$ CFU/well.

For example, the following results were obtained for the compound of Example 4 :

Organism		MIC (μg/ml)
Staphylococcus aureus:	MSQS	0.25
	MRQR	0.5
Streptococcus pneumoniae		0.06
Haemophilus influenzae		8
Moraxella catarrhalis		0.5
Linezolid Resistant Streptococcus pneumoniae		1

MSQS = methicillin sensitive and quinolone sensitive
MRQR = methicillin resistant and quinolone resistant

The activity of the compounds of the invention against MAO-A was tested using a standard in-vitro assay based on human liver enzyme expressed in yeast as described in Biochem. Biophys. Res. Commun. 1991, 181, 1084-1088. . Compounds of the Examples showed Ki values of ≥ 5 μM when measured in such an assay as above. Example 4 showed a Ki value of 8 μM.

It will be appreciated that, as described in our patent application WO 03/072575, compounds with 4-alkyl triazoles generally demonstrate lower MAO-A inhibition than the analogous unsubstituted triazole compounds.

We further disclose compounds of the general formula (I) as hereinbefore described, wherein R^4 is allyl (optionally subsituted on the carbon-carbon double bond by 1,2 or 3 (1-4C)alkyl groups), and compounds wherein R^4 is (2-4C)alkyl substituted with azido. These compounds, such as Reference Examples 2 and 9 have antibacterial activity, and in addition may

be useful as intermediates to other compounds of the formula (I) (particularly where R^4 is (2-4C)alkyl substituted with azido).

Certain intermediates and/or Reference Examples described hereinafter are within the scope of the invention and/or may also possess useful activity, and are provided as a further feature of the invention. In particular, a further aspect of the invention is Reference Example 11.

The invention is now illustrated but not limited by the following Examples in which unless otherwise stated :-

(i) evaporations were carried out by rotary evaporation in-vacuo and work-up procedures were carried out after removal of residual solids by filtration;

(ii) operations were carried out at ambient temperature, that is typically in the range 18-26°C and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;

(iii) column chromatography was used to purify compounds, either by the flash procedure on normal phase silica gel 60, 230-400 mesh, or by the flash procedure on reverse phase silica gel (C-18, RediSep, Isco, Inc.), or by HPLC on reverse phase silica gel (e.g.: Waters YMC-ODS AQ, C-18) using a Gilson 215 Platform, unless otherwise stated;

(iv) yields are given for illustration only and are not necessarily the maximum attainable;

(v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra were generally determined in DMSO-d_6 unless otherwise stated, using a Bruker spectrometer at 300, 400 or 500 MHz; chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) or relative to solvent. Peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; mass spectroscopy was performed using a Micromass Quattro Micro mass spectrometer (for ESP) and an Agilent 1100 MSD instrument (for APCI); optical rotations were determined at 589nm at 20°C using a Perkin Elmer Polarimeter 341;

(vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, LC-MS, TLC, or NMR and identity was determined by mass spectroscopy and/or NMR spectroscopy as appropriate;

(vii) in which the following abbreviations may be used :-

DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; MPLC is medium pressure

liquid chromatography; DMSO is dimethylsulfoxide; $CDCl_3$ is deuterated chloroform; MS is mass spectroscopy; ESP is electrospray; EI is electron impact; CI is chemical ionisation; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; phosphoryl is $(HO)_2$-P(O)-O-; phosphiryl is $(HO)_2$-P-O-; Bleach is "Clorox" 6.15% sodium hypochlorite; DMAP is 4-dimethylaminopyridine; THF is tetrahydrofuran; TFA is trifluoroacetic acid; RT is room temperature; cf. = compare

(viii) temperatures are quoted as °C.

(ix) MP carbonate resin is a solid phase resin for use in acid Scaveging, available from Argonaut Technologies, chemical structure is PS-$CH_2N(CH_2CH_3)_3^+$ $(CO_3^{2-})_{0.5}$

Pro-drug Example 1: *tert*-Butyl {[(5*S*)-3-(5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate



tert-Butyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate (**Intermediate 12,** 175 mg, 0.47 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 201 mg, 0.52 mmol), potassium carbonate (200 mg, 1.45 mmol), and tetrakis(triphenylphosphino)palladium(0) (54 mg, 0.047 mmol) were suspended in DMF (2.5 ml) and water (0.25 ml). The mixture was heated at 80 °C for 1 hour, poured into water, extracted with ethyl acetate, dried over sodium sulfate and evaporated. The residue was purified by column chromatography (silica gel, 1 to 5 % methanol in dichloromethane). The material thus obtained was triturated with dichloromethane: diethyl ether: hexane (1:5:5) followed by filtration and rinsing with diethyl ether:hexane (1:1). The title compound was thus obtained as an off-white solid (110 mg): melting point: 186 °C.

MS (electrospray): 553 (M+1) for $C_{27}H_{29}FN_6O_6$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.41 (s, 9H); 3.36 (dd, 1H); 3.52 (dd, 1H); 3.62 (dd, 1H); 3.67 (dd, 1H); 3.96 (dd, 1H); 4.04 (s, 2H); 4.29 (t, 1H); 4.86 (d, 2H); 4.92 (m, 1H); 5.18 (m,

1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.77 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Intermediate 1: Acetic acid (*5R*)-3-(3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester



(*5R*)-3-(3-Fluorophenyl)-5-hydroxymethyloxazolidin-2-one (40 g, 0.189 mol, see Upjohn WO 94-13649) was suspended by stirring in dry dichloromethane (400 ml) under nitrogen. Triethylamine (21 g, 0.208 mol) and 4-dimethylaminopyridine (0.6 g, 4.9 mmol) were added, followed by dropwise addition of acetic anhydride (20.3 g, 0.199 mol) over 30 minutes, and stirring continued at ambient temperature for 18 hours. Saturated aqueous sodium bicarbonate (250 ml) was added, the organic phase separated, washed with 2% sodium dihydrogen phosphate, dried (magnesium sulfate), filtered and evaporated to give the desired product (49.6 g) as an oil.

MS (ESP): 254 (MH^+) for $C_{12}H_{12}FNO_4$

NMR(300MHz) ($CDCl_3$) δ: 2.02 (s, 3H); 3.84 (dd, 1H); 4.16 (t, 1H); 4.25 (dd, 1H); 4.32 (dd, 1H); 4.95 (m, 1H); 6.95 (td, 1H); 7.32 (d, 1H); 7.43 (t, 1H) ; 7.51 (d, 1H).

Intermediate 2: Acetic acid (*5R*)-3-(3-fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester



Acetic acid (*5R*)-3-(3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester (**Intermediate 1**, 15.2 g, 60 mmol) was dissolved in a mixture of chloroform (100 ml) and acetonitrile (100 ml) under nitrogen, and silver trifluoroacetate (16.96 g, 77 mmol) were added. Iodine (18.07 g, 71 mmol) was added in portions over 30 minutes to the vigorously stirred solution, and stirring continued at ambient temperature for 18 hours. As reaction was not complete, a further portion of silver trifluoroacetate (2.64 g, 12 mmol) was added and stirring continued for 18 hours. After filtration, the mixture was added to sodium thiosulfate solution (3%, 200 ml) and dichloromethane (200 ml), and the organic phase separated, washed with sodium

thiosulfate (200 ml), saturated aqueous sodium bicarbonate (200 ml), brine (200 ml), dried (magnesium sulfate), filtered and evaporated. The crude product was suspended in *iso*hexane (100 ml), and sufficient diethyl ether added to dissolve out the brown impurity while stirring for 1 hour. Filtration gave the desired product (24.3 g) as a cream solid.

MS (ESP): 380 (MH^+) for $C_{12}H_{11}FINO_4$

NMR(300MHz) (DMSO-d_6) δ: 2.03 (s, 3H); 3.82 (dd, 1H); 4.15 (t, 1H); 4.24 (dd, 1H); 4.30 (dd, 1H); 4.94 (m, 1H); 7.19 (dd, 1H); 7.55 (dd, 1H) ; 7.84 (t, 1H).

Intermediate 3: (*5R*)-3-(3-Fluoro-4-iodophenyl)-5-hydroxymethyloxazolidin-2-one



Acetic acid (*5R*)-3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl ester (**Intermediate 2**, 30 g, 79 mmol) was treated with potassium carbonate (16.4 g, 0.119 mmol) in a mixture of methanol (800 ml) and dichloromethane (240 ml) at ambient temperature for 25 minutes, then immediately neutralised by the addition of acetic acid (10 ml) and water (500 ml). The precipitate was filtered, washed with water, and dissolved in dichloromethane (1.2 L), the solution washed with saturated sodium bicarbonate, and dried (magnesium sulfate). Filtration and evaporation gave the desired product (23 g).

MS (ESP): 338 (MH^+) for $C_{10}H_9FINO_3$

NMR (300MHz)(DMSO-d_6) δ: 3.53 (m, 1H); 3.67 (m, 1H); 3.82 (dd, 1H); 4.07 (t, 1H); 4.70 (m, 1H); 5.20 (t, 1H); 7.21 (dd, 1H); 7.57 (dd, 1H); 7.81 (t, 1H).

Intermediate 4: [(*5R*)-3-(3-Fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate



(*5R*)-3-(3-Fluoro-4-iodophenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one (**Intermediate 3**, 25.0 g, 74.2 mmol) was stirred in dichloromethane (250 ml) at 0 °C. Triethylamine (10.5 g, 104 mmol) was added followed by methanesulfonyl chloride (11.2 g, 89.0 mmol) and the reaction was stirred overnight, slowly warming to room temperature. The yellow solution was diluted with sodium bicarbonate and the compound was extracted using dichloromethane

(3x250 ml). The organic layer was dried (magnesium sulfate), filtered and concentrated to give the desired product as a light yellow solid (30.3 g).

MS (ESP): 416 (MH^+) for $C_{11}H_{11}FINO_5S$

^{1}H-NMR(300MHz) (DMSO-d_6): 3.24 (s, 3H); 3.82 (dd, 1H); 4.17 (t, 1H); 4.43-4.52 (m, 2H); 4.99-5.03 (m, 1H); 7.21 (dd, 1H); 7.55 (dd, 1H); 7.83 (t, 1H).

Intermediate 5: (5*R*)-5-(Azidomethyl)-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one



[(5*R*)-3-(3-Fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate (**Intermediate 4**, 6.14 g, 14.7 mmol) was dissolved in *N*,*N*-dimethylformamide (50 ml). Sodium azide (1.92 g, 29.6 mmol) was added and the reaction was stirred at 75 °C overnight. The yellow mixture was poured into half-saturated sodium bicarbonate and extracted using ethyl acetate. The organic layer was washed three times with water, dried (magnesium sulfate), filtered, and concentrated to give the title compound as a yellow solid (4.72 g).

MS (ESP): 363 (MH^+) for $C_{10}H_8FIN_4O_2$

^{1}H-NMR(300MHz) (DMSO-d_6): 3.72-3.82 (m, 3H); 4.14 (t, 1H); 4.89-4.94 (m, 1H); 7.22 (dd, 1H); 7.57 (dd, 1H); 7.83 (t, 1H).

Intermediate 6: (5*R*)-3-(3-Fluoro-4-iodophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



(5*R*)-5-(Azidomethyl)-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one (**Intermediate 5**, 30.3 g, 72.9 mmol) was stirred in 1,4-dioxane. Bicyclo[2.2.1]hepta-2,5-diene (40.3 g, 437 mmol) was added and the reaction was heated at 100 °C overnight. The resulting brown mixture was filtered and the desired product was obtained as a light brown solid (14.8 g).

MS (ESP): 389 (MH^+) for $C_{12}H_{10}FIN_4O_2$

^{1}H-NMR(300Mz) (DMSO-d_6: 3.90 (dd, 1H); 4.23 (t, 1H); 4.84 (d, 2H); 5.11-5.18 (m, 1H), 7.14 (dd, 1H); 7.49 (dd, 1H); 7.76 (s, 1H); 7.82 (t, 1H); 8.17 (s, 1H).

Intermediate 7: (5*R*)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



(5*R*)-3-(3-Fluoro-4-iodophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 6**, 2 g, 5.15 mmol), bis(pinacolato)diboron, 2.62 g (10.3 mmol), potassium acetate, 2.5 g (25.5 mmol), and 1,1'-[bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichoromethane complex, 0.38 g (0.52 mmol) were suspended in DMSO, 15 ml. The mixture was heated at 80 °C for 40 minutes to give a clear black solution. Ethyl acetate (150 ml) was then added and the mixture was filtered through celite, washed with saturated NaCl (2 x 100 ml), dried over sodium sulfate and evaporated. The dark residue was purified by chromatography (silica gel, 40 to 100% ethyl acetate in hexane, followed by 1-5% acetonitrile in ethyl acetate) to give the product as a crystalline tan solid, 1.97g (98%). (note – highly colored impurities elute ahead of product band, extended elution required to obtain product).

NMR(300Mz) (DMSO-d_6) δ: 1.28 (s, 12H), 3.91 (dd, 1H); 4.23 (t, 1H); 4.83 (d, 2H); 5.14 (m, 1H); 7.27 (dd, 1H); 7.37 (dd, 1H); 7.62 (t, 1H); 7.75 (s, 1H); 8.16 (s, 1H).

Alternatively:

(5*R*)-3-(3-Fluoro-4-iodophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 6**, 5 g, 12.9 mmol), pinacolborane, 2.9 ml (20 mmol), triethylamine, 5.4 ml (39 mmol), and trans-dichlorobis(triphenylphosphine)palladium (II), 0.92 g (1.3 mmol) were dissolved in dioxane, 70 ml. The mixture was heated at 100 °C for 90 minutes to give a black solution, which was concentrated, dissolved in ethyl acetate, washed with brine, dried over sodium sulfate and evaporated. The residue was purified by chromatography (silica gel, 0 to 5% methanol in dichloromethane with 1% triethylamine) to give the product as a light brown solid, 3.1 g.

Intermediate 8: 5-Bromo-*N*-hydroxypyridine-2-carboximidoyl chloride



5-Bromopyridine-2-carbaldehyde oxime (49.5 g, 246.3 mmol) was dissolved in DMF (150 ml) followed by addition of *N*-chlorosuccinimide (39.5 g, 295.5 mmol). HCl gas was then bubbled in the solution for 20 seconds to initiate the reaction, which was then allowed to stir for 1 hr. The reaction was poured into distilled water (1 L) and the precipitate was collected by vacuum filtration. The filter cake was washed with distilled water (2 x 500 ml) and then dried overnight in a vacuum oven at 60 °C (–30 inches Hg) to yield the product as a white powder (55 g).

^{1}H-NMR(300Mz)($CDCl_3$) δ: 7.73 (d, 1H); 8.09 (d, 1H); 8.73 (s, 1H); 12.74 (s, 1H).

NOTE: ***Lachrymator.***

Intermediate 8a: 5-Bromopyridine-2-carbaldehyde oxime



5-Bromo-pyridine-2-carbaldehyde (X. Wang et al, Tetrahedron Letters 41 (2000), 4335-4338) (60 g, 322 mmol) was added to methanol (700 ml) and then water was added (700 ml) followed by addition of hydroxylamine hydrochloride (28 g, 403 mmol). Sodium carbonate (20.5 g, 193.2 mmol) in water (200 ml) was added and the reaction was stirred for 30 minutes. Water (500 ml) was then added and the precipitate was filtered and washed with water (2 x 300 ml) to give the desired product (60 g).

NMR (DMSO-d_6) δ: 7.75 (d, 1H); 8.09 (t, 2H), 8.72 (s, 1H); 11.84 (s, 1H).

Intermediate 9: [3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl butyrate



5-Bromo-*N*-hydroxypyridine-2-carboximidoyl chloride (**Intermediate 8**, 46 g, 195.7 mmol) was added to EtOAc (200 ml) followed by addition of allyl butyrate (145 ml, 1020.4 mmol) and the solution was cooled to 0 °C. Triethylamine (30 ml, 215.8 mmol) in EtOAc (100 ml) was then added dropwise over 1 hour. The reaction was then allowed to stir for 1 hour at 0 °C and then EtOAc (1 L) was added. The precipitate was removed by vacuum filtration and the filtrate was concentrated *in vacuo* to yield the product (65 g).

^{1}H-NMR(DMSO-d_6) δ: 0.81 (t, 3H); 1.43 (m, 2H); 2.24 (t, 2H); 3.21 (dd, 1H); 3.54 (dd, 1H); 4.13 (dd, 1H); 4.23 (dd, 1H); 5.01 (m,1H); 7.85 (dd, 1H); 8.12 (dd, 1H); 8.81 (d, 1H).

Intermediate 10: (5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl butyrate



(+) Isomer assigned as (5*S*) based on comparison with Chem. Lett. 1993 p.1847.

Racemic [3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl butyrate (**Intermediate 9**, 80 g, 0.244 mol) was dissolved in acetone (4 L), and 0.1 M potassium phosphate buffer (pH~7) (4 L) was added with vigorous stirring to give a clear yellow solution. PS-lipase (1.45 g, Sigma cat no L-9156) was added and the mixture was gently stirred at ambient temp. for 42 hrs. The solution was divided into 3 equal volumes of ~2.6 L and each was extracted with dichloromethane (2 x 1 L), the pooled organic phases were dried over sodium sulfate and evaporated. The unreacted [(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl butyrate was isolated via flash column chromatography (9:1 hexane: ethyl acetate) as a clear yellow oil, 36.4 g (45.5%).

Intermediate 11: [(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl butyrate (**Intermediate 10**, 16.88 g, 0.051 mol) was dissolved in methanol (110 ml). 50% Aqueous sodium hydroxide (3.6 ml, 0.068 mol) was added. The solution was stirred at RT for 15 minutes, 1M HCl (75 ml) was added, followed by concentration *in vacuo* to ~100 ml total volume. Water (~50 ml) was added, and the white precipitate was collected and rinsed with water. The filtrate was extracted twice with ethyl acetate, the organic layers were pooled, dried over sodium sulfate and evaporated. The solid residue was collected and rinsed with 10: 1 hexane: ethyl acetate, then combined with the initial precipitate before drying in vacuo to give the title compound as a white crystalline solid, 12.3 g (93%). Chiral HPLC analysis indicated < 0.5 % of the (-) isomer was present. $[\alpha]_D$ = + 139 (c = 0.01 g/ml in methanol).

Intermediate 12: *tert*-Butyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (**Intermediate 11,** 200 mg, 0.78 mmol) and and tetrabutyl ammonium iodide (2 mg, catalytic amount) were dissolved in THF (3 ml), sodium hydride (60% dispersion in mineral oil, 65 mg, 1.63 mmol) was added carefully and the suspension was stirred for 5 minutes then cooled to 0 °C. *tert*-Butyl bromoacetate (0.25 ml, 1.69 mmol), was added and the suspension was stirred at room temperature for 5 hours. The mixture was carefully diluted with water and 1M HCl and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, evaporated and purified *via* chromatography (silica gel, 10 to 20% ethyl acetate in hexanes). Evaporation of the product containing fractions and drying *in vacuo* yielded *tert*-butyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate as a thick oil (179 mg).

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.40 (s, 9H); 3.29 (dd, 1H); 3.47 (dd, 1H); 3.60 (dd, 1H); 3.65 (dd, 1H); 4.02 (d, 2H); 4.91 (m, 1H); 7.85 (d, 1H); 8.12 (dd, 1H); 8.77 (d, 1H).

Reference Example 2: (5*R*)-3-[4-(6-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-fluorophenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



2-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 13,** 210 mg, 0.71 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 302 mg, 0.78 mmol), potassium carbonate (293 mg, 2.12 mmol), and tetrakis(triphenylphosphino)palladium(0) (82 mg, 0.071 mmol) were suspended in DMF (4 ml) and water (0.4 ml). The mixture was heated at 80 °C for 1 hour, poured into water, extracted with ethyl acetate, dried over sodium sulfate and evaporated. The residue was purified by column chromatography (silica gel, 1 to 5 % methanol in dichloromethane). The

material thus obtained was triturated with dichloromethane: diethyl ether: hexane (1:5:5) followed by filtration and rinsing with diethyl ether:hexane (1:1). The title compound was thus obtained as an off-white solid (160 mg): melting point: 162 °C.

MS (electrospray): 479 (M+1) for $C_{24}H_{23}FN_6O_4$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.27 (dd, 1H); 3.48 – 3.60 (m, 3H); 3.96 (dd, 1H); 4.01 (dt, 2H); 4.29 (t, 1H); 4.86 (d, 2H); 4.93 (m, 1H); 5.14 (dd, 1H); 5.18 (m, 1H); 5.24 (dd, 1H); 5.87 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.81 (s, 1H).

Intermediate 13: 2-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (200 mg, 0.78 mmol) and and tetrabutyl ammonium iodide (2 mg, catalytic amount) were dissolved in THF (3 ml), sodium hydride (60% dispersion in mineral oil, 65 mg, 1.63 mmol) was added carefully and the suspension was stirred for 5 minutes then cooled to 0 °C. Allyl bromide (0.15 ml, 1.74 mmol), was added and the suspension was stirred at room temperature for 5 hours. The mixture was carefully diluted with water and 1M HCl and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, evaporated and purified *via* chromatography (silica gel, 10 to 20% ethyl acetate in hexanes). Evaporation of the product containing fractions and drying *in vacuo* yielded 2-{(5*S*)-5-[(allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine as a thick oil (214 mg).

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.21 (dd, 1H); 3.52 – 3.58 (m, 3H); 3.99 (dt, 2H); 4.91 (m, 1H); 5.12 (dt, 1H); 5.22 (dt, 1H); 5.86 (m, 1H); 7.85 (d, 1H); 8.11 (dd, 1H); 8.77 (d, 1H).

Example 3: {[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetic acid



tert-Butyl {[(5*S*)-3-(5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate (**Pro-drug Example 1,** 940 mg, 1.7 mmol was combined with trifluoroacetic acid (12 ml) and stirred to give a clear brown solution. The mixture was stirred for 45 minutes at room temperature then concentrated to give a thick brown oil. The material was sonnicated with diethyl ether to give a solid residue, the ether was decanted off and the procedure was repeated again with diethyl ether then with diethyl ether: dichloromethane (1:1) and the solid was dried *in vacuo*. The title compound was thus obtained as an off-white solid (840 mg): melting point: 190 °C.

MS (electrospray): 497 (M+1) for $C_{23}H_{21}FN_6O_6$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.35 (dd, 1H); 3.55 (dd, 1H); 3.66 (m, 2H); 3.96 (dd, 1H); 4.08 (s, 2H); 4.29 (t, 1H); 4.86 (d, 2H); 4.92 (m, 1H); 5.18 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Example 4: 2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-*N*-methylacetamide



{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetic acid (**Example 3,** 500 mg, 1.0 mmol), pentafluorophenol (370 mg, 2.0 mmol), 4-(dimethylamino)pyridine (3 mg, 0.025 mmol) and DMF (1 ml) were combined to give a clear solution. 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (390 mg, 2.0 mmol) was added, the solution was stirred at room temperature for 4 hours and diluted with ethyl acetate. The mixture was washed with water and saturated sodium chloride, dried over sodium sulphate and evaporated to give the reactive pentafluorophenyl ester as a crude sticky solid (662 mg) which was utilized without further characterization or purification.

The pentafluorophenyl ester (331 mg, 0.5 mmol) was combined with methylamine (2M THF solution, 3 ml, 6 mmol) and dioxane (3 ml). The mixture was warmed to 60 °C for 1.5 hours, evaporated, redissolved in methanol and adsorbed on silica gel. Purification by flash chromatography (silica gel, 0.5-5% methanol/dichloromethane) gave a solid which was

triturated with ether and dried in vacuo to give the title compound as an off-white solid (135 mg). Mp 153-156 °C

MS (electrospray): 510 (M+1) for $C_{24}H_{24}FN_7O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.61 (d, 3H); 3.35 (dd, 1H); 3.54 (dd, 1H); 3.64 (d, 2H); 3.92 (s, 2H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.96 (m, 1H); 5.18 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.65 (bs, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 8.00 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Example 5: 2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-*N*,*N*-dimethylacetamide



{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetic acid (**Example 3,** 500 mg, 1.0 mmol), pentafluorophenol (370 mg, 2.0 mmol), 4-(dimethylamino)pyridine (3 mg, 0.025 mmol) and DMF (1 ml) were combined to give a clear solution. 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (390 mg, 2.0 mmol) was added, the solution was stirred at room temperature for 4 hours and diluted with ethyl acetate. The mixture was washed with water and saturated sodium chloride, dried over sodium sulphate and evaporated to give the reactive pentafluorophenyl ester as a crude sticky solid (662 mg) which was utilized without further characterization or purification.

The pentafluorophenyl ester (331 mg, 0.5 mmol) was combined with dimethylamine (2M THF solution, 3 ml, 6 mmol) and dioxane (3 ml). The mixture was warmed to 60 °C for 1.5 hours, evaporated, redissolved in methanol and adsorbed on silica gel. Purification by flash chromatography (silica gel, 0.5-5% methanol/dichloromethane) gave a solid which was triturated with ether and dried in vacuo to give the title compound as an off-white solid (155 mg). Mp 166-168 °C

MS (electrospray): 524 (M+1) for $C_{25}H_{26}FN_7O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.79 (s, 3H); 2.88 (s, 3H); 3.38 (dd, 1H); 3.52 (dd, 1H); 3.62 (m, 2H); 3.96 (dd, 1H); 4.20 (s, 2H); 4.29 (t, 1H); 4.86 (d, 2H); 4.92 (m, 1H); 5.18 (m,

1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Example 6: (5*R*)-3-{3-Fluoro-4-[6-((5*S*)-5-{[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl}-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetic acid (**Example 3,** 200 mg, 0.4 mmol), pentafluorophenol (150 mg, 0.82 mmol), 4-(dimethylamino)pyridine (3 mg, 0.025 mmol) and DMF (2 ml) were combined to give a clear solution. 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (160 mg, 0.83 mmol) was added, the solution was stirred at room temperature for 45 minutes and diluted with ethyl acetate. The mixture was washed with water and saturated sodium chloride, dried over sodium sulphate and evaporated to give the reactive pentafluorophenyl ester as a crude sticky solid (265 mg) which was utilized without further characterization or purification.

The pentafluorophenyl ester was combined with 1-methylpiperazine (0.25 ml, 2.26 mmol) and dioxane (4 ml). The mixture was warmed to 60 °C for 20 minutes, evaporated and purified by flash chromatography (silica gel, 0.5-20% methanol/dichloromethane) to give a solid (135 mg) that was dissolved in dioxane (10 ml) with warming. HCl (0.4 M solution in dioxane, 0.68 ml, 0.272 mmol) was added to give a precipitate. The suspension was diluted with diethyl ether (10 ml), filtered, rinsed with diethyl ether and dried in vacuo to give the title compound as an off-white solid (140 mg). Mp 165-175 °C

MS (electrospray): 579 (M+1) for $C_{28}H_{31}FN_8O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.75 (s, 3H); 2.98 (bs, 2H); 3.36 (bm, 3H); 3.54 (dd, 1H); 3.56 (s, 2H); 3.64 (bm, 2H); 3.96 (dd, 2H); 4.23 – 4.38 (m, 4H); 4.86 (d, 2H); 4.95 (m, 1H); 5.19 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.68 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H); 10.40 (bs, 1H).

Example 7: (5*R*)-3-[3-Fluoro-4-(6-{(5*S*)-5-[(3-hydroxypropoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



3-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}propan-1-ol (**Intermediate 14,** 370 mg, 1.17 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 457 mg, 1.18 mmol), potassium carbonate (460 mg, 3.33 mmol), and tetrakis(triphenylphosphino)palladium(0) (140 mg, 0.12 mmol) were suspended in DMF (5 ml) and water (0.5 ml). The mixture was heated at 80 °C for 35 minutes, adsorbed directly onto silica gel and dried *in vacuo*. Purification by column chromatography (silica gel, 0.5 to 10 % methanol in dichloromethane) gave an off-white solid. The material thus obtained was dissoled in methanol (4 ml) with warming and allowed to cool to give a precipitate. The mixture was diluted with diethyl ether (20 ml) and sonnicated to give a fine solid, which was collected, rinsed with diethyl ether and dried *in vacuo*. The pure title compound was thus obtained as an off-white solid (235 mg): melting point: 176 °C.

MS (electrospray): 497 (M+1) for $C_{24}H_{25}FN_6O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.63 (p, 2H); 3.25 (dd, 1H); 3.42 (t, 2H); 3.46 – 3.55 (m, 5H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.89 (m, 1H); 5.19 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.81 (s, 1H).

Intermediate 14: 3-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}propan-1-ol



2-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 12,** 350 mg, 1.18 mmol) and and 9-borabicyclo[3.3.1]nonane (BBN, 0.5 M solution in THF, 7 ml, 3.5 mmol) were combined at 0 °C. The cold bath was removed and the solution was stirred at room temperature for 45 minutes. The solution was cooled to 0 °C, then sodium hydroxide (50% aqueous solution, 1 ml) and hydrogen peroxide (30% aqueous solution, 0.5

ml) were carefully added. The cold bath was removed and the mixture was stirred at room temperature for 1.5 hours. The mixture was diluted with ethyl acetate, washed with water, then saturated sodium chloride and dried over sodium sulfate. Evaporation followed by filtration through a small pad of silica gel, rinsing with 50% ethyl acetate in hexane yielded 3-{[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}propan-1-ol as a thick yellow oil (370 mg).

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.81 (p, 2H); 3.33 (dd, 1H); 3.49 (dd, 1H); 3.64 (m, 2H); 3.70 (t, 2H); 3.73 (t, 2H); 4.94 (m, 1H); 7.83 (dd, 1H); 7.89 (d, 1H); 8.64 (d, 1H).

Example 8: (5*S*)-3-[3-Fluoro-4-[6-((5*S*)-5-{[(2-hydroxyethyl)]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



2-{[(5*S*)-3-(5- Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethanol (**Intermediate 15,** 0.302 g, 0.84 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 313 mg, 0.81 mmol), potassium carbonate (223 mg, 1.62 mmol), and tetrakis(triphenylphosphino)palladium(0) (0.049 g, 0.042 mmol) were suspended in DMF (5.6 ml) and water (0.56 ml). The mixture was heated at 85 °C for 1 hour, extracted with ethyl acetate and water. The ethyl acetate layer was dried over sodium sulfate and evaporated. The residue was purified by column chromatography (silica gel, 100% ethyl acetate to 30 % methanol in ethyl acetate). The title compound was thus obtained as an off-white solid (0.160 g): melting point: 162 °C.

MS (electrospray): 483.2 (M+1) for $C_{23}H_{23}FN_6O_5$

^{1}H-NMR (300 MHz, Chloroform-D) δ: 2.08-2.01 (t, 1H); 3.52-3.36 (m, 1H), 3.44-3.61 (m, 1H); 3.64-3.76 (m, 6H); 3.98-4.03 (m, 1H); 4.18 (t, 1H); 4.81(m, 1H); 4.83 (s, 1H); 4.94-5.03 (m, 1H); 5.07-5.15 (m, 1H); 7.20-7.24(dd, 1H); 7.48 (dd, 1H); 7.75 (s, 1H); 7.79 (s, 1H); 7.85-7.88 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.74 (s, 1H).

Intermediate 15: {[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihroisoxazol-5-yl]methoxy}acetaldehyde



2-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 13,** 0.500 g, 1.7 mmol) dissolved/ slurred in THF:water (1:1, 8 ml). A catalytic amount of osmium tetroxide was added to the stirring reaction mixture. Sodium periodate (1.80 g, 8.4 mmol) was added and the reaction mixture was stirred vigorously. A large amount of precipitate formed. The reaction was monitored by TLC and was complete after 20 mins of stirring at room temperature. The reaction mixture was partitioned between dichloromethane and water. The dichloromethane layer was dried over magnesium sulfate and evaporated. The title product was obtained as a dark oil (0.525 g).

MS (electrospray): 299.0 (M+1)

^{1}H-NMR (300 MHz, Chloroform-D) δ: 3.31-3.53 (m, 2H); 3.70-3.71 (m, 2H); 4.89-4.98 (m, 1H); 5.23 (s, 2H); 7.76-7.85 (m, 2H); 8.59 (m, 1H); 9.64 (s, 1H)

Intermediate 16: 2-{[(5*S*)-3-(5- Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethanol



{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihroisoxazol-5-yl]methoxy}acetaldehyde (**Intermediate 15,** 0.525 g, 0.18 mmol) was dissolved in MeOH (10 ml), and then allowed to cool to 0 °C using ice/water bath. Sodium borohydride (0.131 g, 0.36 mmol) was slowly added. After addition completion, the mixture was allowed to stir warm up to room temperature then stirred for 30 minutes. The solution was diluted with ethyl acetate, washed twice with water, dried over magnesium sulfate and evaporated. Purification by column chromatography (silica gel, 100% hexanes to 100% ethyl acetate) yielded the title compound (0.287 g).

MS (electrospray): 303.08 (M+1)

^{1}H-NMR (300 MHz, Chloroform-D) δ: 3.29-3.55 (m, 2H); 3.63-3.71 (m, 6H); 4.89-5.01 (m, 1H); 7.81-7.91 (m, 2H); 8.64 (m, 1H)

Reference Example 9: (5*R*)-3-[4-(6-{(5*S*)-5-[(2-Azidoethoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-fluorophenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



2-{(5*S*)-5-[(2-Azidoethoxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 17,** 360 mg, 1.1 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 425 mg, 1.1 mmol), potassium carbonate (460 mg, 3.33 mmol), and tetrakis(triphenylphosphino)palladium(0) (132 mg, 0.11 mmol) were suspended in DMF (5 ml) and water (0.5 ml). The mixture was heated at 80 °C for 40 minutes, adsorbed directly onto silica gel and dried *in vacuo*. Purification by column chromatography (silica gel, 0.5 to 5 % methanol in dichloromethane) gave a thick oil. The oil was dissolved in dichloromethane (4 ml), diluted with diethyl ether (20 ml) and sonnicated to give a fine solid, which was collected, rinsed with diethyl ether and dried *in vacuo*. The title compound was thus obtained as an off-white solid (205 mg): melting point: 148 °C.

MS (electrospray): 508 (M+1) for $C_{23}H_{22}FN_9O_4$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.29 (dd, 1H); 3.39 (t, 2H); 3.53 (dd, 1H); 3.62 – 3.68 (m, 4H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.93 (m, 1H); 5.19 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.81 (s, 1H).

Intermediate 17: 2-{(5*S*)-5-[(2-Azidoethoxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine



2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethanol (**Intermediate 16,** 320 mg, 1.06 mmol) and and triphenylphosphine (500 mg, 1.9 mmol) were dissolved in tetrahydrofuran (5 ml) and cooled to 0 °C. Diphenylphosphorylazide (0.46 ml, 2.1 mmol) was added followed by the dropwise addition of diisopropylazodicarboxylate (0.42 ml, 2.1 mmol) over 10 minutes. The cold bath was removed and the solution was stirred at room temperature for 30 minutes. The cloudy solution was cooled to 0 °C, then methanol (1 ml)

was added. The cold bath was removed and the mixture was stirred at room temperature for 1.5 hours. The solution was stirred for 5 minutes, then concentrated *in vacuo* to give a thick oil. Purification by column chromatography (silica gel, 10 to 25 % ethyl acetate in hexane) gave the title compound as a clear oil (285 mg).

^{1}H-NMR (400 MHz, $CDCl_3$) δ: 3.36 (t, 2H); 3.39 (dd, 1H); 3.52 (dd, 1H); 3.70 (d, 2H); 3.72 (t, 2H); 4.96 (m, 1H); 7.84 (dd, 1H); 7.90 (d, 1H); 8.65 (d, 1H).

Example 10: (5*S*)-3-[3-Fluoro-4-(6-{(5*S*)-5-[(2-morpholin-4-ylethoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



4-(2-{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihyroisoxazol-5-yl]methoxy}-ethyl)morpholine (**Intermediate 18**, 405 mg, 1.09 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7**, 493 mg, 1.3 mmol), potassium carbonate (360 mg, 2.6 mmol), and tetrakis(triphenylphosphino)palladium(0) (0.075 g, 0.065 mmol) were suspended in DMF (8.9 ml) and water (0.89 ml). The mixture was heated at 85 °C for 1 hour under nitrogen. After reaction completion, the reaction mixture was poured into water. The precipitate formed was filtered and washed with water. The wet filter cake was dissolved in 1:1 methanol:acetonitrile then purified by column chromatography (silica gel, 1:1 ethyl acetate: methanol). The title compound was thus obtained as beige crystalline solid (0.350g): melting point: 171 °C.

MS (electrospray): 552.2 (M+1) for $C_{27}H_{30}FN_7O_5$

^{1}H-NMR (300 MHz, DMSO-d6) δ: 2.36 (m, 5H); 74-3.57 (m, 10 H); 3.94-3.99 (m, 1H); 4.28-4.34 (m, 1H); 4.86-4.88 (m, 2H); 5.14-5.24 (m, 1H); 7.42-7.44 (dd, 1H); 7.57-7.62 (dd, 1H); 7.67-7.72 (m, 1H); 7.78 (s, 1H); 7.98-8.01(d, 1H); 8.05-8.08 (d, 1H); 8.19 (s, 1H); 8.82 (s, 1H).

Intermediate 18: 4-(2-{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihyroisoxazol-5-yl]methoxy} ethyl)morpholine



{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihroisoxazol-5-yl]methoxy}acetaldehyde (**Intermediate 15,** 0.068 g, 0.23 mmol) was dissolved anhydrous dichloromethane (3 ml) under nitrogen. Morpholine (0.018 g, 0.21 mmol) was added to the reaction mixture followed by sodium triacetoxy borohydride (0.063 g, 0.29 mmol). The reaction was allowed to stir at room temperature for 18 hrs. Saturated sodium bicarbonate solution was added to the reaction mixture. Dichloromethane was added and the layers were separated. The dichloromethane layer was washed with brine, dried over magnesium sulfate and evaporated. The dark oil was purified by chromatography (10% hexanes in ethyl acetate to 40% hexanes in ethyl acetate). The title compound was obtained as an oil (0.030 g).

MS (electrospray): 372.0 (M+1)

^{1}H-NMR (300 MHz, Chloroform-D) δ: 2.44-2.47 (m, 4H); 2.54-2.58 (m, 2H); 3.30-3.52 (m, 2H); 3.59-3.73 (m, 8H); 4.89-4.98 (m, 1H); 7.81-7.91 (m, 2H); 8.64 (s, 1H)

Reference Example 11: (5*S*)-3-(4-{6-[(5S)-5-(Ethoxymethy)-4,5-dihydroisoxazol-3-yl]pyridine-3yl}-3-fluorophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



5-Bromo-2-[(5S)-5-(ethoxymethyl)-4,5-dihydroisoxazol-3-yl]pyridine) (**Intermediate 19,** 240 mg, 0.84 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 310 mg, 0.80 mmol), potassium carbonate (350 mg, 2.5 mmol), and tetrakis(triphenylphosphino)palladium(0) (50 mg, 0.04 mmol) were suspended in DMSO (4.3 ml) and water (0.43 ml). The mixture was heated at 85 °C for 1 hour under nitrogen. After reaction completion, the reaction mixture extracted with ethyl acetate, washed with water,

dried over sodium sulfate and evaporated. The residue was purified by column chromatography (silica gel, 100% dichloromethane to 10% methanol in dichloromethane). The solid collected was recrystallized from dichloromethane/ether. The title compound was thus obtained as beige crystalline solid (122 mg): melting point: 171 °C.

MS (electrospray): 467.2 (M+1) for $C_{23}H_{23}FN_6O_4$

^{1}H-NMR (300 MHz, DMSO-d6) δ: 1.07-1.12 (t, 3H); 3.19-3.28 (m, 2H); 3.42-3.56 (m, 5H); 3.93-3.98 (m, 1H); 4.26-4.32 (m, 1H); 4.84-4.87 (m, 2H); 5.14-5.22 (m, 1H); 7.40-7.42 (dd, 1H); 7.56-7.60 (dd, 1H); 7.66-7.72 (m, 1H); 7.77 (s, 1H); 7.98-8.00(d, 1H); 8.04-8.07 (d, 1H); 8.18 (s, 1H); 8.81 (s, 1H).

Intermediate 19: 5-Bromo-2-[(5S)-5-(ethoxymethyl)-4,5-dihydroisoxazol-3-yl]pyridine



{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (**Intermediate 11,** 300 mg, 1.0 mmol) was dissolved in anhydrous THF (4.5 ml) under nitrogen. Sodium hydride (60% dispersion in mineral oil) (100 mg, 2.3 mmol) was added to the stirring reaction mixture. The reaction mixture was cooled to 0 °C. Ethyl iodide (0.2 ml, 2.3 mmol) was slowly added. The reaction was allowed to warm up to room temperature and was monitored by TLC. The reaction was complete in 18 hours. The mixture was quenched with methanol, diluted with ethyl acetate and washed with water. The ethyl acetate layer was dried over sodium sulfate, evaporated and purified *via* chromatography (silica gel, 10 to 20% ethyl acetate in hexanes). Evaporation of the product containing fractions and drying *in vacuo* yielded the title compound as a thick oil (240 mg).

^{1}H-NMR (300 MHz, Chloroform-D) δ: 1.17-1.21 (m, 3H); 3.29-3.50 (m, 2H); 3.52-3.62 (m, 4H); 4.89-4.98 (m, 1H); 7.81-7.92 (m, 2H); 8.64 (s, 1H)

Example 12: (5*S*)-3-(4-{6-[(5S)-5-(Ethoxymethy)-4,5-dihydroisoxazol-3-yl]pyridine-3yl}-3-fluorophenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



5-Bromo-2-{(5S)-5-[(2-methoxyethoxy)methyl]-4,5-dihydroisoxazol-3-yl]pyridine (**Intermediate 20,** 375mg, 1.2 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 443 mg, 1.14 mmol), potassium carbonate (315 mg, 2.3 mmol), and tetrakis(triphenylphosphino)palladium(0) (69 mg, 0.06 mmol) were suspended in DMF (6.75 ml) and water (0.68 ml). The mixture was heated at 85 °C for 1 hour under nitrogen. After reaction completion, the reaction mixture was poured into water. The precipitate formed was filtered and washed with water. The filter cake was crystallized from methanol/acetonitrile, filtered and washed with ether. The title compound was thus obtained as beige crystalline solid (152 mg): melting point: 150.9 °C.

MS (electrospray): 497.2 (M+1) for $C_{24}H_{25}FN_6O_5$

^{1}H-NMR (300 MHz, Chloroform-D) δ: 3.19 (s, 3H); 3.24-3.27 (m 1H); 3.34-3.43 (m, 3H); 3.48-3.60 (m, 4H); 3.81-3.60 (m, 1H); 4.05 (m, 1H); 4.65 (m, 2H); 4.83 (m, 1H); 4.95 (m, 1H); 7.04-7.09 (s, 2H); 7.22-7.31 (d, 1H); 7.58-7.63 (d, 1H); 7.63-77 (d, 1H); 7.86-7.89 (d, 1H); 8.56 (s, 1H).

Intermediate 20: 5-Bromo-2-{(5S)-5-[(2-methoxyethoxy)methyl]-4,5-dihydroisoxazol-3-yl]pyridine



2-{[(5*S*)-3-(5- Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethanol (**Intermediate 16,** 393 mg, 1.3 mmol) was dissolved in anhydrous THF (13 ml) under nitrogen. Sodium hydride (60% dispersion in mineral oil) (91 mg, 3.9 mmol) was added to the stirring reaction mixture. The reaction mixture was cooled to 0 °C. Methyl iodide (0.163 ml, 2.0 mmol) was slowly added. The reaction mixture was monitored by TLC. The reaction was complete in 1 hour and was allowed to warm up to room temperature overnight. The mixture was quenched with methanol, diluted with ethyl acetate and washed with water. The ethyl acetate layer dried over sodium sulfate, evaporated. Evaporation yielded the title compound as a thick oil (375 mg).

^{1}H-NMR (300 MHz, Chloroform-D) δ: 3.21 (s, 3H); 3.14-3.57(m, 8H); 4.84-4.93 (m, 1H); 7.86 (d, 1H); 8.09 (d, 1H); 8.77 (s, 1H)

Example 13: *N*-(2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)methanesulfonamide



N-(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl) methanesulfonamide (**Intermediate 22,** 270 mg, 0.71 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 280 mg, 0.72 mmol), potassium carbonate (300 mg, 2.17 mmol), and tetrakis(triphenylphosphino)palladium(0) (100 mg, 0.087 mmol) were suspended in DMF (4 ml) and water (0.5 ml). The mixture was heated at 80 °C for 1 hour, adsorbed directly onto silica gel and dried *in vacuo*. Purification by column chromatography (silica gel, 1 to 10 % methanol in ethyl acetate) gave an off-white solid. The solid was dissolved in methanol with heating (4 ml), cooled to room temperature to give a precipitate, diluted with diethyl ether (10 ml) and sonnicated to give a fine solid, which was collected, rinsed with diethyl ether and dried *in vacuo*. The title compound was thus obtained as an off-white solid (70 mg): melting point: 170 °C.

MS (electrospray): 560 (M+1) for $C_{24}H_{26}FN_7O_6S$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.88 (s, 3H); 3.11 (q, 2H); 3.29 (dd, 1H); 3.48-3.56 (m, 3H); 3.60 (d, 2H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.92 (m, 1H); 5.19 (m, 1H); 7.07 (t, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Intermediate 21: (2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)amine



2-{(5*S*)-5-[(2-Azidoethoxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 17,** 630 mg, 1.93 mmol) was dissolved in dichloromethane (20 ml) and methanol (6 ml) and water (1.5 ml) were added to give a biphasic mixture.

Triphenylphosphine bound polystyrene resin (Argonaut Technologies, Inc. Foster City, CA USA) (1.57 mmol/g, 3.2 g, 5.02 mmol) was added and the resulting suspension was stirred for 3 days at room temperature. The resin was filtered off and rinsed with methanol: dichloromethane (1:3, 200 ml). The filtrate was concentrated to give the title compound as a thick yellow oil (575 mg). This crude material was utilized as an intermediate without further purification.

MS (electrospray): 301 (M+1) for $C_{11}H_{14}BrN_3O_2$

Intermediate 22: *N*-(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl) methanesulfonamide



(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)amine (**Intermediate 21,** 280 mg, 0.93 mmol) and 4-dimethylaminopyridine (2 mg, 0.02 mmol) were dissolved in dichloromethane (2 ml) and pyridine (1 ml) then cooled to 0 °C. Methanesulfonyl chloride (0.37 ml, 4.76 mmol) was added dropwise and the solution was stirred at 0 °C for 1 hour, diluted with dichloromethane, washed with 0.2M HCl, then saturated sodium chloride. The solution was dried over sodium sulfate, evaporated, triturated with ether: hexane (1:1) and dried in vacuo to give the crude title compound as a thick oil (275 mg) which was used as an intermediate without further purification.

MS (electrospray): 379 (M+1) for $C_{12}H_{16}BrN_3O_4S$

Example 14: *N*-(2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)acetamide



N-(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl) acetamide (**Intermediate 23,** 295 mg, 0.86 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one

(**Intermediate 7,** 340 mg, 0.88 mmol), potassium carbonate (360 mg, 2.61 mmol), and tetrakis(triphenylphosphino)palladium(0) (120 mg, 0.104 mmol) were suspended in DMF (4 ml) and water (0.5 ml). The mixture was heated at 80 °C for 1 hour, adsorbed directly onto silica gel and dried *in vacuo*. Purification by column chromatography (silica gel, 1 to 20 % methanol in ethyl acetate) gave an off-white solid. The solid was dissolved in methanol with heating (4 ml), cooled to room temperature to give a precipitate, diluted with diethyl ether (10 ml) and sonnicated to give a fine solid, which was collected, rinsed with diethyl ether and dried *in vacuo*. The title compound was thus obtained as an off-white solid (200 mg): melting point: 134 °C.

MS (electrospray): 524 (M+1) for $C_{25}H_{26}FN_7O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.77 (s, 3H); 3.18 (q, 2H); 3.27 (dd, 1H); 3.46 (t, 2H); 3.54 (dd, 1H); 3.57 (d, 2H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.91 (m, 1H); 5.19 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.88 (bt, 1H); 7.99 (d, 1H); 8.05 (d, 1H); 8.18 (s, 1H); 8.81 (s, 1H).

Intermediate 23: *N*-(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl) acetamide



(2-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)amine (**Intermediate 21,** 280 mg, 0.93 mmol) and 4-dimethylaminopyridine (2 mg, 0.02 mmol) were dissolved in dichloromethane (2 ml) and pyridine (1 ml) then cooled to 0 °C. Methanesulfonyl acetic anhydride (0.45 ml, 4.76 mmol) was added dropwise and the solution was stirred at 0 °C for 1 hour, diluted with dichloromethane, washed with 0.2M HCl, then saturated sodium chloride. The solution was dried over sodium sulfate and evaporated to give the crude title compound as an off-white solid (300 mg) which was used as an intermediate without further purification.

MS (electrospray): 343 (M+1) for $C_{13}H_{16}BrN_3O_3$

Example 15: {[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetonitrile



{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetonitrile (**Intermediate 24,** 165 mg, 0.56 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 240 mg, 0.62 mmol), potassium carbonate (250 mg, 1.81 mmol), and tetrakis(triphenylphosphino)palladium(0) (64 mg, 0.055 mmol) were suspended in DMF (3 ml) and water (0.5 ml). The mixture was heated at 80 °C for 30 minutes, filtered, evaporated and purified by column chromatography (silica gel, 0.5 to 5 % methanol in dichloromethane). The material thus obtained was crystallized from methanol: dichloromethane (10:1) followed by filtration and rinsing with diethyl ether. The title compound was obtained as an off-white solid (110 mg): melting point: 90-115 °C.

MS (electrospray): 478 (M+1) for $C_{23}H_{20}FN_7O_4$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.28 (dd, 1H); 3.56 (dd, 1H); 3.68 (dd, 1H); 3.74 (dd, 1H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.54 (s, 2H); 4.86 (d, 2H); 4.97 (m, 1H); 5.19 (m, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Intermediate 24: {[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetonitrile



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (**Intermediate 11,** 325 mg, 1.26 mmol) and and tetrabutyl ammonium iodide (2 mg, catalytic amount) were dissolved in THF (5 ml), sodium hydride (60% dispersion in mineral oil, 110 mg, 2.75 mmol) was added carefully and the suspension was stirred for 5 minutes then cooled to 0 °C. Bromoacetonitrile (0.20 ml, 2.87 mmol), was added and the suspension was stirred at room temperature for 6 hours. The mixture was carefully diluted with water and 1M HCl and extracted with ethyl

acetate. The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, evaporated and purified *via* chromatography (silica gel, 10 to 30% ethyl acetate in hexanes). Evaporation of the product containing fractions and drying *in vacuo* yielded the title compound as a thick oil (169 mg).

^{1}H-NMR (400 MHz, $CDCl_3$) δ: 3.36 (dd, 1H); 3.54 (dd, 1H); 3.77 (dd, 1H); 3.81 (dd, 1H); 4.35 (s, 2H); 4.98 (m, 1H); 7.85 (dd, 1H); 7.90 (d, 1H); 8.65 (d, 1H).

Example 16: (5*R*)-3-[3-Fluoro-4-(6-{(5*S*)-5-[(2-hydroxy-2-methylpropoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



1-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-2-methylpropan-2-ol (**Intermediate 26,** 235 mg, 0.71 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 280 mg, 0.72 mmol), potassium carbonate (320 mg, 2.32 mmol), and tetrakis(triphenylphosphino)palladium(0) (88 mg, 0.076 mmol) were suspended in DMF (3 ml) and water (0.5 ml). The mixture was heated at 80 °C for 60 minutes, diluted with acetonitrile (15 ml), filtered, evaporated and purified by column chromatography (silica gel, 0.5 to 5 % methanol in dichloromethane). The material thus obtained was crystallized from methanol: diethyl ether (1:1) followed by filtration and rinsing with diethyl ether. The title compound was obtained as an off-white solid (140 mg): melting point: 180-187 °C.

MS (electrospray): 511 (M+1) for $C_{25}H_{27}FN_6O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 1.04 (s, 6H); 3.23 (s, 2H); 3.30 (dd, 1H); 3.52 (dd, 1H); 3.62 (d, 2H); 3.96 (dd, 1H); 4.30 (m, 2H); 4.86 (d, 2H); 4.92 (m, 1H); 5.19 (m, 1H); 7.43 (dd, 1H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.77 (s, 1H); 8.00 (d, 1H); 8.06 (d, 1H); 8.19 (s, 1H); 8.82 (s, 1H).

Example 20: *N*-(2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)-*N*-methylglycine



tert-Butyl *N*-(2-{[(5*S*)-3-(5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)-*N*-methylglycinate (**Intermediate 31,** 115 mg, 0.19 mmol) was dissolved in 15 ml trifluoroacetic acid then warmed to 60 °C for 6 hours. The solution was concentrated to dryness and the residue was dissolved in water (1 ml). The product solution was filtered through a small column (2g C18 reverse phase silica, 0 to 20% acetonitrile in water) and the eluent was evaporated. The residue was dissolved in methanol: dichloromethane (2:1, 3 ml), then ether (20 ml) was added and the resulting solid was collected and dried under vacuum to yield the title compound as an off-white solid (75 mg), mp 135-140 °C.

MS (electrospray): 554 (MH^+) for $C_{26}H_{28}FN_7O_6$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.71 (s, 3H); 3.17-3.39 (m, 4H); 3.54 (dd, 1H); 3.61 (bm, 2H); 3.74-3.85 (2 x bd, 3H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 4.94 (m, 1H); 5.18 (m, 1H); 7.42 (d, 1H); 7.59 (d, 1H); 7.68 (t, 1H); 7.77 (s, 1H); 7.99 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H).

Intermediate 31: *tert*-Butyl *N*-(2-{[(5*S*)-3-(5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)-*N*-methylglycinate



tert-Butyl *N*-(2-{[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)-*N*-methylglycinate (**Intermediate 32,** 0.19 g, 0.44 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (0.26 g, 0.67 mmol), potassium carbonate (0.20 g, 1.45 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.051 g, 0.044 mmol) were combined in DMF (3

Intermediate 25: Ethyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (**Intermediate 11,** 2.0 g, 7.78 mmol) was dissolved in THF (25 ml) and cooled to 0 °C, sodium hydride (60% dispersion in mineral oil, 0.58 g, 14.5 mmol) was added carefully, the cold bath was removed and the suspension was stirred for 30 minutes then cooled again to 0 °C. Tetrabutyl ammonium iodide (10 mg, catalytic amount) and ethyl bromoacetate (1.3 ml, 11.7 mmol) were added and the suspension was stirred and allowed to warm slowly to room temperature for 16 hours. The mixture was carefully diluted with 0.5 M HCl (100 ml) and extracted with ethyl acetate (100 ml). The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, evaporated and purified *via* chromatography (silica gel, 20% ethyl acetate in hexanes). Evaporation of the product containing fractions gave a thick oil which was combined with 10 ml hexane and stirred with cooling to give a white solid. The hexane was decanted off and the solid was resuspended in hexane, decanted and dried *in vacuo* to give ethyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate as a white solid (2.2 g).

^{1}H-NMR (400 MHz, $CDCl_3$) δ: 1.26 (t, 3H); 3.41-3.55 (m, 2H); 3.76 (d, 2H); 4.16 (s, 2H); 4.19 (q, 2H); 4.98 (m, 1H); 7.83 (dd, 1H); 7.89 (d, 1H); 8.64 (s, 1H).

Intermediate 26: 1-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-2-methylpropan-2-ol



Ethyl {[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}acetate (**Intermediate 25,** 255 mg, 0.74 mmol) was dissolved in THF (5 ml) and cooled to -70 °C, Methyl magnesium bromide (3M solution in diethyl ether, 0.65 ml, 1.95 mmol) was added dropwise over several minutes, the solution was stirred at -70 °C for 1.5 hours, the cold bath was removed and the mixture was stirred for an additional 1.25 hours at room temperature. The mixture was poured into 0.5 M HCl (50 ml) and extracted with ethyl acetate (50 ml). The

organic layer was washed with saturated sodium chloride, dried over sodium sulfate and evaporated to give the title compound as a thick oil (239 mg).

^{1}H-NMR (400 MHz, $CDCl_3$) δ: 1.16 (s, 6H); 3.36 (s, 2H); 3.37 (dd, 1H); 3.51 (dd, 1H); 3.70 (d, 2H); 4.97 (m, 1H); 7.85 (dd, 1H); 7.90 (d, 1H); 8.65 (s, 1H).

Example 17: 2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl L-isoleucinate



(5*S*)-3-[3-Fluoro-4-[6-((5*S*)-5-{[(2-hydroxyethyl)]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Example 8,** 400 mg, 0.83 mmol), was dissolved in anhydrous DMF (8 ml) while stirring under nitrogen. A catalytic amount of DMAP was added. BOC-L-isoleucine, (383 mg, 1.70 mMol) was added to the reaction mixture followed by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (336 mg, 1.67mmol). The reaction was allowed to stir for 18 hours. After reaction completion, the reaction mixture was worked up with ethyl acetate/water. The ethyl acetate layer was dried over magnesium sulfate and evaporated. The residue, a dark oil, was purified by column chromatography (silica gel, 100% ethyl acetate to 10 % methanol in ethyl acetate). The solid collected was recrystalized from dichloromethane/ether. The solid, *tert*-butyl {(1*S*,2*S*)-1-[(2-{[(5*S*)-3-(5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethoxy)methyl]-2-methylbutyl}carbamate, was dissolved in dioxane (anhydrous) (2 ml) to which was added 4M HCl in dioxane (2.5 ml). The reaction mixture was stirred under nitrogen. The solid that precipitated out was filtered and washed with ether. The title compound (as its HCl salt) was obtained as a solid (340 mg) after drying at 80 °C under vacuum for 18 hours. Melting point: 119 °C

MS (electrospray): 596.2 (M+1) for $C_{29}H_{34}FN_7O_6$

^{1}H-NMR (300 MHz, DMSO-d6) δ: 0.75-0.86 (m, 6H); 1.2-1.35 (m, 1 H); 1.8-1.9 (m, 2H), 3.18-3.32 (m, 2H), 3.38-3.81(m, 4H), 4.18-4.51 (m. 2H), 4.81-4.91(t, 1H); 5.14-5.24 (m, 1H);

7.42-7.44 (dd, 1H); 7.57-7.62 (dd, 1H); 7.67-7.72 (m, 1H); 7.78 (s, 1H); 7.98-8.01(d, 1H); 8.05-8.08 (d, 1H); 8.19 (s, 1H); 8.82 (s, 1H).

Example 18: 2-{[(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl *N*,*N* dimethylglycinate hydrochloride



(5*S*)-3-[3-Fluoro-4-[6-((5*S*)-5-{[(2-hydroxyethyl)]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Example 8,** 400 mg, 0.83 mmol), was dissolved in anhydrous DMF (8 ml) while stirring under nitrogen. A catalytic amount of DMAP (300 mg, 2.8 mmol) was added. Dimethyl glycine (206 mg, 2.0 mmol) was added to the reaction mixture followed by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (403 mg, 2.0 mmol). The reaction was allowed to stir for 3 hours. After reaction completion, the reaction mixture was worked up with ethyl acetate/water. The ethyl acetate layer was dried over magnesium sulfate and evaporated. The residue, an oil, was purified by crystallization from dichloromethane/ether. The solid was dissolved in dioxane (anhydrous) (3 ml) to which was added 4M HCl in dioxane (0.15 ml, 0.6 mmol). The reaction mixture was stirred under nitrogen. The solid that precipitated out was filtered and washed with ether to give the title compound as a solid (340 mg) after drying at 40 °C under vacuum for 18 hours.

MS (electrospray): 568.2 (M+1) for $C_{27}H_{30}FN_7O_6$

^{1}H-NMR (300 MHz, DMSO-d6) δ: 2.83 (s, 6H); 3.18-3.29 (m, 1H); 3.48-3.58 (m, 1 H); 3.60-3.78 (m, 5H), 3.53-4.01 (m, 2H), 4.22 (m, 2H), 4.30-4.33 (m. 2H), 4.86 (s, 2H); 5.14-5.24 (m, 1H); 7.42-7.44 (dd, 1H); 7.57-7.62 (dd, 1H); 7.67-7.72 (m, 1H); 7.78 (s, 1H); 7.98-8.01(d, 1H); 8.05-8.08 (d, 1H); 8.19 (s, 1H); 8.82 (s, 1H); 10.23-10.36 (s, 1H).

Example 19: ((5*R*)-3-{4-[6-((5*S*)-5-{[3-(Dimethylamino)-2-hydroxypropoxy]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]-3-fluorophenyl}-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



1-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-3-(dimethylamino)propan-2-ol (**Intermediate 28,** 215 mg, 0.60 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7,** 285 mg, 0.73 mmol), potassium carbonate (250 mg, 1.8 mmol), and tetrakis(triphenylphosphino)palladium(0) (70 mg, 0.06 mmol) were suspended in DMF (4 ml) and water (0.4 ml). The mixture was heated at 80 °C for 1 hour, allowed to cool, filtered and adsorbed on silica gel. The adsorbed material was purified by column chromatography [silica gel, (1 to 10 % methanol, 0.1 to 2 % triethylamine) in dichloromethane]. The material thus obtained was triturated with diethyl ether followed by filtration and rinsing with diethyl ether to give the free base of the title compound (180 mg). This material was dissolved in warm dioxane (5 ml), HCl (4M solution in dioxane, 0.1 ml) was added, then diluted with diethyl ether to give a precipitate. The solids were collected and rinsed with diethyl ether to give the hydrochloride salt of the title compound as an off-white solid (170 mg): melting point: 110-115 °C.

MS (electrospray): 540 (M+1) for $C_{26}H_{30}FN_7O_5$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 2.74 (d, 3H); 2.77 (d, 3H); 3.06 (m, 2H); 3.25-3.65 (m, 6H); 3.96 (dd, 1H); 4.02 (m, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 5.19 (m, 1H); 5.72 (bs, 1H); 7.42 (dd, 1H); 7.59 (dd, 1H); 7.68 (t, 1H); 7.76 (s, 1H); 8.00 (d, 1H); 8.07 (d, 1H); 8.18 (s, 1H); 8.82 (s, 1H); 9.33 (bs, 1H).

Intermediate 27: 5-Bromo-2-{(5*S*)-5-[(oxiran-2-ylmethoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridine



2-{(5*S*)-5-[(Allyloxy)methyl]-4,5-dihydroisoxazol-3-yl}-5-bromopyridine (**Intermediate 13,** 220 mg, 0.74 mmol) and 3-chloroperbenzoic acid (70-75% aqueous slurry, 230 mg, 0.93

mmol) were combined in dichloromethane (2 ml) and stirred at room temperature for 16 hours. The suspension was diluted with ethyl acetate, washed with aqueous sodium thiosulfate, 0.2 M sodium hydroxide, and saturated sodium chloride. The organic solution was dried over sodium sulfate and purified by chromatography (silica gel, 10 to 100% ethyl acetate / hexanes) to give the title compound as a white solid (100 mg).

^{1}H-NMR (400 MHz, $CDCl_3$) 2.59 (m, 1H); 2.78 (m, 1H); 3.14 (m, 1H); 3.38 and 3.33 (2 x dd, 1H); 3.43 – 3.53 (m, 2H); 3.67 (dd, 1H), 3.71- 3.77 (m. 1H), 3.88 and 3.85 (2 x t, 1H); 4.95 (m, 1H); 7.83 (dd, 1H); 7.90 (d, 1H); 8.65 (d, 1H).

Intermediate 28: 1-{[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}-3-(dimethylamino)propan-2-ol



5-Bromo-2-{(5*S*)-5-[(oxiran-2-ylmethoxy)methyl]-4,5-dihydroisoxazol-3-yl}pyridine (**Intermediate 27,** 195 mg, 0.62 mmol) was dissolved in THF (1 ml) and isopropanol (2 ml). Dimethylamine (2M solution in THF, 1 ml, 2 mmol) was added and the solution was stirred at room temperature for 1 day. The solution was concentrated under vacuum to give the title compound as a crude oil (215 mg).

MS (electrospray): 359 (M+1) for $C_{14}H_{20}BrN_3O_3$

Intermediate 29: (5*R*)-3-(3-Fluoro-4-{6-[(5*S*)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl}phenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



[(5*S*)-3-(5-Bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methanol (**Intermediate 11,** 0.277 g, 1.08 mmol), (5*R*)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 7**, 0.35 g, 0.9 mmol), potassium carbonate (0.622 g, 4.5 mmol), and tetrakis(triphenylphosphino)palladium(0) (0.1 g, 0.09 mmol) were combined and suspended in DMF (7 ml) and water (1 ml). The mixture was heated at 75 °C for 2 hours, then was poured into cold water(30ml). The solids formed were collected, rinsed with water and washed with dichloromethane(2x10ml), the solids were then dissolved in warm trifluoroethanol(2ml), and further purified by column chromatography,

eluting with 8% methanol in dichloromethane to give the title compound as a white solid (0.193g).

MS (ESP): 439.22 (M+1) for $C_{21}H_{19}FN_6O_4$

NMR(300Mz)(DMSO-d_6) δ: 3.36 – 3.58 (m, 4H); 3.95 (dd, 1H); 4.29 (t, 1H); 4.78 (m, 1H); 4.86 (d, 2H); 5.02 (t, 1H); 5.18 (m, 1H); 7.41 (dd, 1H); 7.58 (dd, 1H); 7.69 (t, 1H); 7.77 (s, 1H); 7.98 (d, 1H); 8.05 (dd, 1H); 8.18 (s, 1H); 8.78 (s, 1H).

Intermediate 30: [(5*S*)-3-(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}pyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methyl 4-nitrophenyl carbonate



(5*R*)-3-(3-Fluoro-4-{6-[(5*S*)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl}phenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (**Intermediate 29,** 200 mg, 0.46 mmol), was dissolved in DMF (3 ml) and pyridine (0.5 ml), then cooled to 0 °C. 4-Nitrophenyl chloroformate (140 mg, 0.70 mmol) was added and the mixture was allowed to stir at 0 °C for 2 hours. An additional portion of 4-nitrophenylchloroformate (110 mg, 0.55 mmol) was added and the mixture was stirred at room temperature for 2 hours, diluted with ethyl acetate, washed with 0.2 M HCl then saturated sodium chloride, dried over sodium sulfate and evaporated. The residue was suspended in dichloromethane: diethyl ether (1:1), the solids were filtered off and rinsed with dichloromethane: diethyl ether (1:1) to give the title compound as an off-white solid (115 mg).

MS (electrospray): 604 (MH^+) for $C_{28}H_{22}FN_7O_8$

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 3.40 (dd, 1H); 3.63 (dd, 1H); 3.96 (dd, 1H); 4.30 (t, 1H); 4.38 (dd, 1H); 4.49 (dd, 1H); 4.86 (d, 2H); 5.11 (m, 1H); 5.19 (m, 1H); 7.43 (dd, 1H); 7.55 (d, 2H); 7.59 (dd, 1H); 7.69 (t, 1H); 7.76 (s, 1H); 7.99 (d, 1H); 8.06 (d, 1H); 8.18 (s, 1H); 8.26 (d, 2H); 8.83 (s, 1H).

ml) and distilled water (0.3 ml) then heated to 80 °C for 30 minutes. The reaction mixture was adsorbed directly onto silica gel then purified by column chromatography (silica gel; 0.5 - 5% MeOH in dichloromethane) to yield a crude residue, which was dissolved in warm methanol (3 ml), then ether (20 ml) was added and the resulting solid was collected and rinsed with ether to yield the title compound as an off-white solid (0.116 g).

MS (electrospray): 610 (MH^+) for $C_{30}H_{36}FN_7O_6$

Intermediate 32: *tert*-Butyl *N*-(2-{[(5*S*)-3-(5-bromopyridin-2-yl)-4,5-dihydroisoxazol-5-yl]methoxy}ethyl)-*N*-methylglycinate



{[(5S)-3-(5-Bromopyridin-2-yl)-4,5-dihroisoxazol-5-yl]methoxy}acetaldehyde (**Intermediate 15,** 170 mg, 0.57 mmol) was dissolved in methanol (3 ml). Sarcosine-*t*-butyl ester hydrochloride (310 mg, 1.70 mmol) was added and the solution was stirred at room temperature for 15 minutes, then cooled to 0 °C. Sodium triacetoxyborohydride (193 mg, 0.91 mmol) was added, the cold bath was removed, and the mixture was stirred for 2.5 hours, diluted with dichloromethane, washed with saturated sodium bicarbonate, dried over sodium sulfate, and evaporated. The material was purified by flash chromatography (silica gel, 20 to 100% ethyl acetate in hexane) to give the title compound as a thick yellow oil (160 mg).

MS (electrospray): 429 (M+1) for $C_{18}H_{26}BrN_3O_4$

Claims

1. A compound of the formula (I), or a pharmaceutically-acceptable salt, or pro-drug thereof,



(I)

wherein:

R^1 is selected from hydrogen, halogen, cyano, methyl, cyanomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methylthio, and (2-4C)alkynyl;

R^2 and R^3 are independently selected from hydrogen, fluoro, chloro and trifluoromethyl;

R^4 is selected from cyanomethyl, carboxymethyl, $-CH_2C(O)NR^5R^6$ and (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkoxy, hydroxy(2-4C)alkoxy, cyano, $-OC(O)R^5$, carboxy, $-C(O)NR^5R^6$, $-S(O)_2R^5$, $-S(O)_2NR^5R^6$, $-NR^5R^6$, $-NHC(O)R^5$and $-NHS(O)_2R^5$];

R^5 and R^6 are independently selected from hydrogen, methyl, cyclopropyl (optionally substituted with methyl), carboxymethyl and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino, carboxy, (1-4C)alkoxy and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy);

or R^5 and R^6 together with a nitrogen to which they are attached form a 4, 5 or 6 membered, saturated heterocyclyl ring, optionally containing 1 further heteroatom (in addition to the linking N atom) independently selected from O, N and S, wherein a $-CH_2-$ group may optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom (providing the nitrogen to which R^5 and R^6 are attached is not thereby quaternised) by 1 or 2 (1-4C)alkyl groups.

2. A compound of formula (I) or a pharmaceutically-acceptable salt, or pro-drug thereof, as claimed in Claim 1, wherein R^1 is selected from hydrogen, chloro, bromo, methyl and fluoromethyl.

3. A compound of formula (I) or a pharmaceutically-acceptable salt, or pro-drug thereof, as claimed in Claim 1 or Claim 2, wherein R^2 and R^3 are independently selected from hydrogen and fluoro.

4. A compound of formula (I) or a pharmaceutically-acceptable salt, or pro-drug thereof, as claimed in Claim 1, Claim 2, or Claim 3, wherein R^4 is selected from carboxymethyl, $-CH_2C(O)NR^5R^6$ and (2-4C)alkyl [substituted by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, $-NR^5R^6$, $-NHS(O)_2R^5$, $-NHC(O)R^5$ and $-OC(O)R^5$].

5. A compound of formula (I) or a pharmaceutically-acceptable salt, or pro-drug thereof, as claimed in any one of the preceding Claims, wherein R^5 and R^6 are independently selected from hydrogen, methyl, l and (2-4C)alkyl (optionally substituted by 1 or 2 substituents independently selected from amino, (1-4C)alkylamino, di-(1-4C)alkylamino and hydroxy; wherein a (1-4C)alkylamino or di-(1-4C)alkylamino group may optionally be substituted on the (1-4C)alkyl chain with carboxy);

or R^5 and R^6 together with a nitrogen to which they are attached form a morpholine or piperazine ring, optionally substituted with a methyl group.

6. A compound of formula (I) or a pharmaceutically-acceptable salt, or pro-drug thereof, as claimed in any one of the preceding Claims, which is a compound of formula (Ia).



(Ia)

7. A pro-drug of a compound as claimed in any one of the previous claims.

8. A method for producing an antibacterial effect in a warm blooded animal which comprises administering to said animal an effective amount of a compound of the invention as claimed in any one of claims 1 to 6, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

9. A compound of the invention as claimed in any one of claims 1 to 6, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament.

10. The use of a compound of the invention as claimed in any one of claims 1 to 6, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal.

11. A pharmaceutical composition which comprises a compound of the invention as claimed in any one of claims 1 to 6, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, and a pharmaceutically-acceptable diluent or carrier.

12. A pharmaceutical composition as claimed in claim 11, wherein said composition comprises a combination of a compound of the formula (I) and an antibacterial agent active against gram-positive bacteria.

13. A pharmaceutical composition as claimed in claim 12, wherein said composition comprises a combination of a compound of the formula (I) and an antibacterial agent active against gram-negative bacteria.

14. A process for the preparation of a compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salts or in-vivo hydrolysable esters thereof, which process comprises a process a) to (l); and thereafter if necessary:

i) removing any protecting groups;

ii) forming a pro-drug (for example an in-vivo hydrolysable ester); and/or

iii) forming a pharmaceutically-acceptable salt;

wherein said processes (a) to (l) are as follows (wherein the variables are as defined in Claim 1 unless otherwise stated):

a) by modifying a substituent in, or introducing a substituent into another compound of the invention;

b) by reaction of one part of a compound of formula (II) (wherein X is a leaving group useful in palladium [0]coupling) with one part of a compound IIa, again with a leaving group

X (wherein Y is an ether or functionalised derivative thereof), such that the pyridyl-phenyl bond replaces the phenyl-X and pyridyl-X bonds;



(II)



(IIa)



c) by reaction of a pyridyl-phenyl carbamate derivative (III) with an appropriately substituted oxirane to form an oxazolidinone ring;



(III)

or by variations on this process in which the carbamate is replaced by an isocyanate or by an amine or/and in which the oxirane is replaced by an equivalent reagent X-CH_2CH(O-optionally protected)CH_2R_1a where X is a displaceable group;



(d) by reaction of a compound of formula (IV) :



(IV)

where X is a replaceable substituent with a compound of the formula (V):



(V)

wherein X' is a replaceable substituent and wherein Y is as hereinbefore defined; wherein the substituents X and X' are chosen to be complementary pairs of substituents known in the art to be suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0);

e) by reaction of a 3-pyridylphenylbiaryl aldehyde derivative (VI) to form an isoxazoline ring at the undeveloped heteroaryl position;



(VI) (VII)

or by variations on this process in which the reactive intermediate (a nitrile oxide VII') is obtained other than by oxidation of an oxime (VII);



(VII')

f) by formation of the triazole ring from a suitably functionalised intermediate in which the isoxazole-pyridyl-phenyl ring system is already formed;



5

g) by cycloaddition via the azide to acetylenes;



h) by reacting aminomethyloxazolidinones with 1,1-dihaloketone sulfonylhydrazones;



i) for R_1 as a 4-halo substituent, by reacting azidomethyl oxazolidinones with halovinylsulfonyl chlorides;



j) by enantioselective esterase hydrolysis of a racemic mixture of esters at that pro-chiral centre, wherein the unwanted isomer may be recycled.



INTERNATIONAL SEARCH REPORT

International Application No
/GB2005/002059

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D413/14 A61K31/4439 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, PAJ, WPI Data, EMBASE, BIOSIS, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/022824 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; GRAVESTOCK, MICHAEL, BARRY; HA) 20 March 2003 (2003-03-20) Claims 1-20; Formula (I); examples 61, 65	1-14
A	PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12, 5 December 2003 (2003-12-05) -& JP 2003 335762 A (MEIJI SEIKA KAISHA LTD), 28 November 2003 (2003-11-28) Claims 1-9; Formula (I); examples 119-121 abstract	1-14

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 September 2005	16/09/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Kirsch, C

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
.../GB2005/002059

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2004/048392 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; CARCANAGUE, DANIEL, ROBERT; GR) 10 June 2004 (2004-06-10) Claims 1-2, 4-19; Formulae (I), (H), (Zd); example 49	1-14
E	WO 2005/058886 A (DONG-A PHARM.CO.,LTD; RHEE, JAE KEOL; IM, WEON BIN; CHO, CHONG HWANG;) 30 June 2005 (2005-06-30) Claims 1-3, 10-12, 14-16; Formula 1; example 22	1-14

INTERNATIONAL SEARCH REPORT

nternational application No.
PCT/GB2005/002059

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 1-7 (in part), 8, 9-14 (in part)
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [X] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Present claims 1-7 and 8-14 relate to prodrugs and to in-vivo hydrolysable esters, respectively, which are defined by reference to a desirable characteristic or property, namely should be broken down in the human or animal body to give a compound of formula (I).

The claims cover all compounds having this property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the prodrugs and the in-vivo hydrolysable esters disclosed page 7, line 1 to page 11, line 26.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International Application No
T/GB2005/002059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03022824 A	20-03-2003	AT 299502 T	15-07-2005
		BR 0212458 A	19-10-2004
		CA 2459766 A1	20-03-2003
		CN 1639136 A	13-07-2005
		DE 60205030 D1	18-08-2005
		EP 1427711 A1	16-06-2004
		WO 03022824 A1	20-03-2003
		HU 0401005 A2	30-08-2004
		JP 2005507386 T	17-03-2005
		MX PA04002303 A	29-06-2004
		NO 20041428 A	08-06-2004
		NZ 531621 A	24-06-2005
		US 2005107435 A1	19-05-2005
		ZA 200401888 A	18-04-2005
JP 2003335762 A	28-11-2003	NONE	
WO 2004048392 A	10-06-2004	AU 2003302404 A1	18-06-2004
		EP 1567532 A1	31-08-2005
		WO 2004048392 A1	10-06-2004
WO 2005058886 A	30-06-2005	WO 2005058886 A1	30-06-2005